0001564590-22-018245 | 10-Q | XBRL Viewer

Cash and cash equivalents

288,400,000

$ 247,833,000

67,243,000

124,184,000

Short-term investments

95,203,000

79,932,000

Long-term investments

$ 70,542,000

56,619,000

Number of operating segment | Segment

$ 230,000,000.0

Debt issuance percentage

2.50%

Convertible Promissory Note | Thirona Bio, Inc.

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

Investment securities

$ 5,000.0

$ 3,000.0

$ 6,900,000

3,000,000.0

Proceeds from investment securities

$ 5,000.0

$ 3,000.0

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

2023-12

Interest rate

6.00%

Insulin

Loss on purchase commitments

$ 79,300,000

82,800,000

Loss on purchase commitments, number of new contracts recognized | Contract

Maximum | AFREZZA product sales

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

Sales return right following product expiration in months

12 months

Minimum | AFREZZA product sales

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

Sales return right following product expiration in months

6 months

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

^[1]

$ 40,000,000.0

Principal prepayment against outstanding term loans

$ 100,000,000.0

Amount outstanding

40,000,000.0

$ 10,000,000.0

Milestone Rights Liability

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

Contingent liability remain payable

$ 65,000,000.0

Milestone Rights Liability | Maximum

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

Contingent liability for milestone payments

$ 90,000,000.0

[1]	In April 2021, the Company prepaid $10.0 million principal balance and amended the MidCap credit facility. The interest rate prior to the amendment was one-month LIBOR (2% floor) plus 6.75% and the maturity date was in August 2024.

Inventories - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
Inventories - Additional Information (Detail) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Inventory [Line Items]
Inventory write-offs	$ 0	$ 0
Pre-launch Inventory
Inventory [Line Items]
Raw materials inventory	$ 800,000	$ 800,000

Collaboration, Licensing and Other Arrangements

3 Months Ended

Mar. 31, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaboration, Licensing and Other Arrangements

8. Collaboration, Licensing and Other Arrangements

Revenue from collaborations and services for the three months ended March 31, 2022 and 2021 are as follows (in thousands):

	Three Months Ended March 31,
	2022		2021
UT License Agreement⁽¹⁾	$	1,348	$	8,999
UT CSA Agreement⁽²⁾		694		—
Cipla License and Distribution Agreement		37		36
Other		87		—
Vertice Pharma Co-Promotion Agreement		—		292
Receptor CLA		—		10
Total revenue from collaborations and services	$	2,166	$	9,337

_________________________

(1)	Amounts consist of revenue recognized for Next-Gen R&D Services for the three months ended March 31, 2022 and R&D Services and License for the three months ended March 31, 2021.

(2)	Amount consists of revenue recognized for Manufacturing Services for the three months ended March 31, 2022.

United Therapeutics License Agreement — In September 2018, the Company and UT entered into an exclusive global license and collaboration agreement (the “UT License Agreement”), pursuant to which UT is responsible for global development, regulatory and commercial activities with respect to Tyvaso DPI. The Company is responsible for manufacturing clinical supplies and commercial supplies of Tyvaso DPI.

Under the terms of the UT License Agreement, the Company received an upfront payment of $45.0 million in October 2018 and four $12.5 million milestone payments between April 2019 and November 2020. The Company will also be entitled to receive low double-digit royalties on net sales of Tyvaso DPI as well as a manufacturing margin on commercial supplies of the product. UT, at its option, may expand the scope of the products covered by the UT License Agreement to include products with certain other active ingredients for the treatment of pulmonary arterial hypertension. Each such optioned product would be subject to UT’s payment to the Company of up to $40.0 million in additional option exercise and development milestone payments, as well as a low double-digit royalty on net sales of any such product.

In August 2021, the Company and United Therapeutics entered into a CSA, pursuant to which the Company is responsible for manufacturing and supplying to United Therapeutics, and United Therapeutics is responsible for purchasing from the Company on a cost-plus basis, Tyvaso DPI and BluHale inhalation profiling devices, as required for commercial distribution and sale by United Therapeutics. In addition, United Therapeutics is responsible for supplying treprostinil at its expense in quantities necessary to enable the Company to manufacture Tyvaso DPI as required by the CSA. Also pursuant to the CSA, UT will remit a reimbursement of certain pre-production costs incurred by the Company to support the manufacturing and supply of Tyvaso DPI.

The activities and deliverables under the CSA and the current development plan resulted in three distinct performance obligations which include: (1) the license, supply of product to be used in clinical development, and continued development and approval support for Tyvaso DPI (“R&D Services and License”); (2) development activities for the next generation of Next-Gen R&D Services; and (3) a material right associated with future commercial manufacturing and supply of product (“Manufacturing Services”).

As amended in October 2021, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) United Therapeutics provides notice to the Company at least 24 months in advance of such renewal that United Therapeutics does not wish to renew the CSA or (ii) the Company provides notice to United Therapeutics at least 48 months in advance of such renewal that the Company does not wish to renew the CSA. The Company and United Therapeutics each have normal and customary termination rights, including termination for material breach that is not cured within a specific timeframe or in the event of liquidation, bankruptcy or insolvency of the other party.

The Company accounted for the contract modification as if it were part of the existing contract since the amendment modified the scope and price of the CSA by extending the term and increasing the occupancy rate. The effect of the modification on the transaction price and on the measure of progress is recognized as an adjustment to revenue as of the date of the modification. The modification did not result in a change the activities and deliverables under the CSA.

Anticipated

Description

Cash Flow

Revenue Allocation⁽¹⁾

Recognition Method

Progress Measure

Revenue

Recognition

(in millions)

Total anticipated cash flow⁽²⁾

463.5

Distinct Performance Obligation

R&D Services and License⁽³⁾

—

Over time

Ratably

Aug 2021 - Oct 2021

⁽⁴⁾

Next-Gen R&D Services⁽⁵⁾

4.8

Over time

Input

% of completion of costs

⁽⁶⁾

Manufacturing Services⁽⁷⁾

458.7

Point in time

Transfer of control

⁽⁸⁾

_________________________

(1)	Allocation is based on management’s assessment of the stand-alone selling price of each performance obligation.

(2)	The total anticipated cash flow includes a transaction price of $64.3 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $399.2 million for future supply of Tyvaso DPI over the remaining term of the CSA.

(3)

The license for the Company’s IP was considered to be interdependent with the development activities to support approval of Tyvaso DPI. A sales-based royalty is promised in exchange for the IP license; therefore, the royalties associated with the license are excluded from the determination of the transaction price and the Company will recognize revenue as the sale of Tyvaso DPI to a patient occurs.

(4)	Represents the period when the revenue for the R&D Services performance obligation was recognized.

(5)

The standalone selling price (“SSP”) for the Next-Gen R&D Services performance obligation was based on industry ratios as well as the Company’s historical R&D projects. The transaction price for the Next-Gen R&D Services was based on fixed consideration which was allocated between performance obligations as discussed in note (2) above.

(6)

The Next-Gen R&D Services performance obligation will be satisfied over time using the input method based on the costs incurred to date as a percentage of the total estimated costs to fulfill the contract. Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer.

(7)

Pre-production activities under the CSA, such as facility expansion services and certain other administrative services, were considered bundled services that are part of the Company’s Manufacturing Services performance obligation, given the nature of the Company’s contractual responsibilities and ASC 606 requirements.

(8)

The Manufacturing Services performance obligation will be recognized as control of manufactured products is transferred to UT. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of transaction price includes a material right related to manufacturing services in the amount of $144.5 million. The total anticipated cash flow is based on the Company’s estimated production and the ultimate cash flows may vary as manufacturing purchase orders are received.

As of March 31, 2022, deferred revenue consisted of $25.7 million, of which $1.1 million was classified as current and $24.6 million was classified as long-term on the condensed consolidated balance sheet.

Vertice Pharma Co-Promotion Agreement — In December 2020, the Company entered into a co-promotion agreement with Vertice Pharma where the Company’s sales force will promote Thyquidity to adult endocrinologists, pediatric endocrinologists and other healthcare providers who treat hypothyroidism. Following the commercial launch of Thyquidity, in consideration of the sales and promotional activities provided by the Company’s sales force, Vertice Pharma is obligated to pay fixed quarterly payments to the Company, as well as variable consideration based on gross profits resulting from all sales of Thyquidity. Vertice Pharma launched Thyquidity in collaboration with the Company in February 2021.

In September 2021, the Company and Vertice Pharma mutually agreed that the Company would cease promotional activities under the co-promotion agreement effective September 30, 2021, other than certain transitional activities that continued until October 15, 2021. The Company and Vertice Pharma are currently negotiating a final settlement of all obligations related to the termination of the co-promotion agreement.

As of March 31, 2022, the Company fully reserved $0.8 million of revenue from the co-promotion of Thyquidity, which was recognized as allowance for credit losses – collaborations and services, which is included in accounts receivable, net in the condensed consolidated balance sheet.

Thirona Collaboration Agreement — In June 2021, the Company and Thirona entered into a collaboration agreement to evaluate the therapeutic potential of Thirona’s compound for the treatment of pulmonary fibrosis. If initial studies are promising, the Company can exercise certain rights to seek a full license to the compound for clinical development and commercialization. The parties will perform their respective obligations and provide reasonable support for research, clinical development and regulatory strategy. The

collaboration agreement will be accounted for under ASC 808, Collaborative Agreements; however, no consideration will be exchanged between the parties. The Company will expense the costs incurred as research and development in the condensed consolidated statements of operations.

Biomm Supply and Distribution Agreement — In May 2017, the Company and Biomm entered into a supply and distribution agreement for the commercialization of Afrezza in Brazil. Under this agreement, Biomm was responsible for pursuing regulatory approvals of Afrezza in Brazil, including from the Agência Nacional de Vigilância Sanitária (“ANVISA”) and, with respect to pricing matters, from the Camara de Regulação de Mercado de Medicamentos (“CMED”), both of which were received. Biomm commenced product sales in January 2020. There were no shipments of product to Biomm in 2021 or the first quarter of 2022.

Cipla License and Distribution Agreement — In May 2018, the Company and Cipla Ltd. (“Cipla”) entered into an exclusive agreement for the marketing and distribution of Afrezza in India and the Company received a $2.2 million nonrefundable license fee. Under the terms of the agreement, Cipla is responsible for obtaining regulatory approvals to distribute Afrezza in India and for all marketing and sales activities of Afrezza in India. The Company is responsible for supplying Afrezza to Cipla. The Company has the potential to receive an additional regulatory milestone payment, minimum purchase commitment revenue and royalties on Afrezza sales in India once cumulative gross sales have reached a specified threshold.

The nonrefundable licensing fee was recorded in deferred revenue and is being recognized in net revenue – collaborations over 15 years, representing the estimated period to satisfy the performance obligation. The additional milestone payments represent variable consideration for which the Company has not recognized any revenue because of the uncertainty of obtaining marketing approval. As of March 31, 2022, the deferred revenue balance was $1.6 million, of which $0.1 million is classified as current and $1.5 million is classified as long term in the condensed consolidated balance sheets.

Earnings Per Common Share ("EPS")

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

Earnings Per Common Share ("EPS")

11. Earnings per Common Share (“EPS”)

Basic EPS excludes dilution for potentially dilutive securities and is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted EPS reflects the potential dilution under the treasury method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted EPS as they would be antidilutive.

The following tables summarize the components of the basic and diluted EPS computations (in thousands, except per share amounts):

	Three Months Ended March 31,
	2022			2021
EPS — basic and diluted:
Net loss (numerator)	$	(25,998	)	$	(12,916	)
Weighted average common shares (denominator)		251,887			246,631
Net loss per share	$	(0.10	)	$	(0.05	)

Common shares issuable represents incremental shares of common stock which consist of stock options, restricted stock units, warrants, and shares that could be issued upon conversion of the Senior convertible notes and the Mann Group convertible notes.

Potentially dilutive securities outstanding that are considered antidilutive are summarized as follows (in shares):

	Three Months Ended March 31,
	2022		2021
Senior convertible notes		44,120,463		44,120,463
Mann Group convertible notes		7,370,000		7,370,000
Common stock options and PNQs		10,335,424		11,321,734
RSUs and Market RSUs ⁽¹⁾		11,472,698		6,282,279
Employee stock purchase plan		85,633		94,157
Warrants associated with MidCap credit facility		—		1,283,467
Total shares		73,384,218		70,472,100

____________________

(1)	Market RSUs issued in 2020 are included at the maximum share delivery of 300% and the Market RSUs issued in 2021 are included at 0% in accordance with a valuation assessment obtained as of March 31, 2022.

Common and Preferred Stock

3 Months Ended

Mar. 31, 2022

Equity [Abstract]

Common and Preferred Stock

10. Common and Preferred Stock

The Company is authorized to issue 400,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.01 per share, issuable in one or more series as designated by the Company’s board of directors. No other class of capital stock is authorized. As of March 31, 2022 and December 31, 2021, 252,413,434 and 251,477,562 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding.

In February 2018, the Company entered into a controlled equity offering sales agreement (the “CF Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor Fitzgerald, shares of the Company’s common stock having an aggregate offering price of up to $50.0 million or such other amount as may be permitted by the Sales Agreement. Under the Sales Agreement, Cantor Fitzgerald may sell shares by any method deemed to be an “at-the-market offering” as defined in Rule 415 under the Securities Act of 1933, as amended. For the three months ended March 31, 2022, there were no sales under the CF Sales Agreement. For the three months ended March 31, 2021, the Company sold an aggregate of 578,063 shares of the Company’s common stock at a weighted average purchase price of $3.26 per share for an aggregate gross proceeds of approximately $1.9 million pursuant to the CF Sales Agreement.

In the first quarter of 2021, Mann Group converted $0.4 million of interest and $9.6 million of principal into 4,000,000 shares of common stock in accordance with the terms of the Mann Group convertible note.

In the first quarter of 2021, the Company converted $5.0 million principal amount of 2024 convertible notes into 1,666,667 shares of the Company’s common stock in accordance with the terms of the 2024 convertible notes.

For the three months ended March 31, 2022, the Company received $0.7 million from the market price stock purchase plan (“MPSPP”) for 252,176 shares. There were no MPSPP transactions during the three months ended March 31, 2021.

The Company issued 233,401 and 292,981 shares of common stock pursuant to the ESPP for the three months ended March 31, 2022 and 2021, respectively. There were approximately 0.9 million shares of common stock available for issuance under the ESPP as of March 31, 2022.

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Operating Lease Liabilities Payments Due [Abstract]

Stock-Based Compensation - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Parenthetical) (Detail) - RSU shares in Thousands	3 Months Ended
	Mar. 31, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units weighted average grant date fair value \| $ / shares	$ 2.72
Employees Awards \| Share-based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years
Restricted stock units grant date fair value	12,800
Employees Awards \| Share-based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
Restricted stock units grant date fair value	75,615

Commitments and Contingencies - Schedule of Financing Liability Payments (Detail) - USD ($)
$ in Thousands

Mar. 31, 2022

Dec. 31, 2021

2022

^[1]

$ 6,373

9,778

10,023

10,274

10,539

199,091

246,078

(140,165)

(142,485)

Debt issuance costs

(3,040)

(3,091)

Total financing liability

$ 102,873

$ 100,502

[1]	2022 includes amortization of the rent abatement.

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2022

Commitments And Contingencies Disclosure [Abstract]

Schedule of Lease Term and Discount Rate

Financing liability information is as follows (in thousands):

	March 31, 2022			December 31, 2021
Weighted average remaining lease term (in years)	19.6				19.8
Weighted average discount rate		9.0	%		9.0	%

	March 31, 2022			December 31, 2021
Weighted average remaining lease term (in years)		2.4			2.6
Weighted average discount rate		7.3	%		7.3	%

Summary of Lease Information

Three Months Ended

March 31,

2022

2021

Interest expense on financing liability

2,371

—

Lease information is as follows (in thousands):

	Three Months Ended March 31,
	2022		2021
Operating lease costs	$	288	$	350
Variable lease costs		86		111
Cash paid		442		461

Summary of Financing Liability Payments

Financing liability payments as of March 31, 2022 was as follows (in thousands):

	March 31, 2022			December 31, 2021
2022⁽¹⁾	$	6,373		$	6,373
2023		9,778			9,778
2024		10,023			10,023
2025		10,274			10,274
2026		10,539			10,539
Thereafter		199,091			199,091
Total		246,078			246,078
Interest expense		(140,165	)		(142,485	)
Debt issuance costs		(3,040	)		(3,091	)
Total financing liability	$	102,873		$	100,502

_________________________

⁽¹⁾	2022 includes amortization of the rent abatement.

Remaining Purchase Requirements

In May 2021, the Company and Amphastar France Pharmaceuticals S.A.S. (“Amphastar”) amended the Insulin Supply Agreement to extend the term and restructure the annual purchase commitments. In connection with the amendment, the Company agreed to pay $2.0 million of amendment fees, which were recognized in cost of goods sold for the year ended December 31, 2021. The remaining purchase commitments as of March 31, 2022 and March 31, 2021 (pre-amendment) were as follows:

	March 31, 2022			March 31, 2021
2021	€		—	€	7.0 million
2022	€	4.1 million		€	8.5 million
2023	€	8.8 million		€	10.9 million
2024	€	14.6 million		€	14.6 million
2025	€	15.5 million		€	15.5 million
2026	€	19.4 million		€	19.4 million
2027	€	9.2 million		€		—

Schedule of Future Minimum Office And Vehicle Lease Payments

Future minimum office and vehicle lease payments as of March 31, 2022 and December 31, 2021, are as follows (in thousands):

	March 31, 2022		December 31, 2021
2022	$	1,060	$	1,444
2023		463		497
2024		375		409
2025		313		311
Total	$	2,211	$	2,661

Inventories (Tables)

3 Months Ended

Mar. 31, 2022

Inventory Disclosure [Abstract]

Components of Inventory

Inventories consist of the following (in thousands):

	March 31, 2022		December 31, 2021
Raw materials	$	3,201	$	2,703
Work-in-process		3,276		2,522
Finished goods		1,567		1,927
Total inventory	$	8,044	$	7,152

Schedule of Revenue from Collaborations and Services (Detail) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2022

Mar. 31, 2021

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and services

$ 11,992

$ 17,436

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and services | License Agreement | United Therapeutics Corporation

2,166

9,337

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and services | Commercial Supply Agreement | United Therapeutics Corporation

^[1]

1,348

8,999

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and services | License and Distribution Agreement | Cipla Ltd

^[2]

694

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and services | Other

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and services | Co-Promotion Agreement | Vertice Pharma LLC

$ 87

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborations and services | Collaboration and License Agreement | Receptor CLA

292

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

$ 10

[1]	Amounts consist of revenue recognized for Next-Gen R&D Services for the three months ended March 31, 2022 and R&D Services and License for the three months ended March 31, 2021
[2]	Amount consists of revenue recognized for Manufacturing Services for the three months ended March 31, 2022

Earnings Per Common Share ("EPS") - Components of Basic and Diluted EPS Computations (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
EPS — basic and diluted:
Net loss (numerator)	$ (25,998)	$ (12,916)
Weighted average common shares (denominator)	251,887	246,631
Net loss per share	$ (0.10)	$ (0.05)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Components of Basic and Diluted EPS Computations

Earnings Per Common Share ("EPS") (Tables)

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

The following tables summarize the components of the basic and diluted EPS computations (in thousands, except per share amounts):

	Three Months Ended March 31,
	2022			2021
EPS — basic and diluted:
Net loss (numerator)	$	(25,998	)	$	(12,916	)
Weighted average common shares (denominator)		251,887			246,631
Net loss per share	$	(0.10	)	$	(0.05	)

Potential Dilutive Securities Outstanding that are Considered Antidilutive

Potentially dilutive securities outstanding that are considered antidilutive are summarized as follows (in shares):

	Three Months Ended March 31,
	2022		2021
Senior convertible notes		44,120,463		44,120,463
Mann Group convertible notes		7,370,000		7,370,000
Common stock options and PNQs		10,335,424		11,321,734
RSUs and Market RSUs ⁽¹⁾		11,472,698		6,282,279
Employee stock purchase plan		85,633		94,157
Warrants associated with MidCap credit facility		—		1,283,467
Total shares		73,384,218		70,472,100

____________________

(1)	Market RSUs issued in 2020 are included at the maximum share delivery of 300% and the Market RSUs issued in 2021 are included at 0% in accordance with a valuation assessment obtained as of March 31, 2022.

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Undesignated preferred stock, par value	$ 0.01	$ 0.01
Undesignated preferred stock, shares authorized	10,000,000	10,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	252,413,434	251,477,562
Common stock, shares outstanding	252,413,434	251,477,562

Fair Value of Financial Instruments - Fair Value of Financial Instruments (Parenthetical) (Detail) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2021
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of hypothetical yield			9.0
MidCap Credit Facility
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of hypothetical yield	10	10
Note payable, percentage of interest rate increases (decreases)	2.00%	2.00%
Financial liabilities fair value	$ 40.7	$ 40.8
MidCap Credit Facility \| Minimum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	39.0	39.1
MidCap Credit Facility \| Maximum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 42.4	$ 42.7
Mann Group Convertible Notes
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of hypothetical yield	12	12
Note payable, percentage of interest rate increases (decreases)	2.00%	2.00%
Losses on extinguishment of debt		$ (22.1)
Substantial premium based on fair value post modification recognized as additional paid-in capital		$ 22.1
Mann Group Convertible Notes \| Volatility
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of volatility	84.2	85
Mann Group Convertible Notes \| Minimum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 32.8	$ 36.9
Mann Group Convertible Notes \| Maximum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 34.6	$ 38.8
Senior Convertible Notes
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of hypothetical yield	12	12
Note payable, percentage of interest rate increases (decreases)	2.00%	2.00%
Financial liabilities fair value	$ 221.6	$ 237.5
Senior Convertible Notes \| Volatility
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of volatility	83.6	90
Senior Convertible Notes \| Minimum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 211.1	$ 226.6
Senior Convertible Notes \| Maximum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 233.1	$ 249.4

Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables And Accruals [Abstract]
Salary and related expenses	$ 15,083	$ 14,022
Discounts and allowances for commercial product sales	4,191	4,227
Danbury facility buildout	1,374	786
Deferred lease liability	1,194	1,380
Current portion of milestone rights liability	1,088	1,088
Professional fees	1,005	895
Accrued interest	729	2,166
Retail inventory purchase		875
Other	2,467	1,980
Accrued expenses and other current liabilities	$ 27,131	$ 27,419

Commitments and Contingencies - Schedule of Future Minimum Office And Vehicle Lease Payments (Detail) - office and vehicle - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Commitments And Contingencies [Line Items]
Year1	$ 1,060	$ 1,444
Year 2	463	497
Year 3	375	409
Year 4	313	311
Total	$ 2,211	$ 2,661

Condensed Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Total	Convertible Note Mann Group	Convertible Note Interest Mann Group	2024 Convertible Notes	2024 Convertible Note Interest	At-the-market Placement	Common Stock	Common Stock Convertible Note Mann Group	Common Stock Convertible Note Interest Mann Group	Common Stock 2024 Convertible Notes	Common Stock 2024 Convertible Note Interest	Common Stock At-the-market Placement	Additional Paid-in Capital	Additional Paid-in Capital Convertible Note Mann Group	Additional Paid-in Capital Convertible Note Interest Mann Group	Additional Paid-in Capital 2024 Convertible Notes	Additional Paid-in Capital 2024 Convertible Note Interest	Additional Paid-in Capital At-the-market Placement	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2020	$ (180,419)						$ 2,421						$ 2,866,303							$ (3,049,143)
Beginning Balance (in shares) at Dec. 31, 2020							242,118,000
Net issuance of common stock associated with stock options and restricted stock units	397						$ 4						393
Net issuance of common stock associated with stock options and restricted stock units (in shares)							390,000
Issuance of common stock under Employee Stock Purchase Plan	390						$ 3						387
Issuance of common stock under Employee Stock Purchase Plan (in shares)							292,981
Stock-based compensation expense	1,935												1,935
Issuance of common stock pursuant to conversion notes		$ 9,573	$ 427	$ 5,000				$ 38	$ 2	$ 17				$ 9,535	$ 425	$ 4,983
Issuance of common stock pursuant to conversion notes (in shares)								3,830,000	170,000	1,667,000
Issuance of common stock pursuant to payoff of the 2024 convertible note interest					$ 143												$ 143
Issuance of common stock pursuant to payoff of the 2024 convertible note interest (in shares)											27,000
Issuance of at-the-market placement						$ 1,886						$ 6						$ 1,880
Issuance of at-the-market placement (in shares)												578,000
Issuance costs associated with at-the- market placement	(38)												(38)
Net loss	(12,916)																			(12,916)
Ending Balance at Mar. 31, 2021	(173,622)						$ 2,491						2,885,946							(3,062,059)
Ending Balance (in shares) at Mar. 31, 2021							249,073,000
Beginning Balance at Dec. 31, 2021	(209,349)						$ 2,515						2,918,205							(3,130,069)
Beginning Balance (in shares) at Dec. 31, 2021							251,478,000
Net issuance of common stock associated with stock options and restricted stock units	129						$ 4						125
Net issuance of common stock associated with stock options and restricted stock units (in shares)							450,000
Issuance of common stock under Employee Stock Purchase Plan	740						$ 2						738
Issuance of common stock under Employee Stock Purchase Plan (in shares)							233,401
Stock-based compensation expense	2,806												2,806
Issuance of common stock from market price stock purchase plan	684						$ 3						681
Issuance of common stock from Market Price Stock Purchase Plan (in shares)							252,000
Cumulative loss on available-for-sale securities	(1,076)																		$ (1,076)
Net loss	(25,998)																			(25,998)
Ending Balance at Mar. 31, 2022	$ (232,064)						$ 2,524						$ 2,922,555						$ (1,076)	$ (3,156,067)
Ending Balance (in shares) at Mar. 31, 2022							252,413,000

Accounts Receivable (Tables)

3 Months Ended

Mar. 31, 2022

Receivables [Abstract]

Schedule of Accounts Receivable, Net

Accounts receivable, net consists of the following (in thousands):

	March 31, 2022			December 31, 2021
Accounts receivable – commercial
Accounts receivable, gross	$	8,656		$	7,939
Wholesaler distribution fees and prompt pay discounts		(1,201	)		(1,696	)
Reserve for returns		(3,089	)		(2,797	)
Total accounts receivable – commercial, net		4,366			3,446
Accounts receivable – collaborations and services
Accounts receivable, gross		6,224			2,060
Allowance for doubtful accounts		(767	)		(767	)
Total accounts receivable – collaborations and services, net		5,457			1,293
Total accounts receivable, net	$	9,823		$	4,739

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2022

Property Plant And Equipment [Abstract]

Property and Equipment, Net

Property and equipment consists of the following (in thousands):

	Estimated Useful
	Life (Years)		March 31, 2022				December 31, 2021
Land		—	$	875			$	875
Buildings	39-40			17,389				17,389
Building improvements	5-40			38,651				38,651
Machinery and equipment	3-15			55,294				55,334
Furniture, fixtures and office equipment	5-10			2,969				2,969
Computer equipment and software		3		8,360				8,163
Construction in progress		—		15,824		⁽¹⁾		10,892
				139,362				134,273
Less accumulated depreciation				(97,909	)			(97,661	)
Total property and equipment, net			$	41,453			$	36,612

____________________

(1)

Construction in progress includes $7.7 million of equipment under construction for the manufacturing expansion for UT (the “UT Equipment”). The Company acts as agent on behalf of UT for the procurement of the UT Equipment. The Company has received $7.1 million in deposit for this service, which was recognized as deposits from customer in the condensed consolidated balance sheet as of March 31, 2022. See Note 8 – Collaboration, Licensing and Other Arrangements.

Depreciation Expense Related to Property and Equipment

Depreciation expense related to property and equipment for the three months ended March 31, 2022 and 2021 was as follows (in thousands):

Three Months Ended

March 31,

2022

2021

Depreciation Expense

599

460

Accrued Expenses and Other Current Liabilities

3 Months Ended

Mar. 31, 2022

Payables And Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

6. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities were comprised of the following (in thousands):

	March 31, 2022		December 31, 2021
Salary and related expenses	$	15,083	$	14,022
Discounts and allowances for commercial product sales		4,191		4,227
Danbury facility buildout		1,374		786
Deferred lease liability		1,194		1,380
Current portion of milestone rights liability		1,088		1,088
Professional fees		1,005		895
Accrued interest		729		2,166
Retail inventory purchase		—		875
Other		2,467		1,980
Accrued expenses and other current liabilities	$	27,131	$	27,419

Property and Equipment, Net (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 139,362	$ 134,273
Less accumulated depreciation	(97,909)	(97,661)
Total property and equipment, net	41,453	36,612
Land
Property Plant And Equipment [Line Items]
Property and equipment - gross	875	875
Buildings
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 17,389	17,389
Buildings \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	39 years
Buildings \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Building Improvements
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 38,651	38,651
Building Improvements \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Building Improvements \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Machinery and Equipment
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 55,294	55,334
Machinery and Equipment \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	3 years
Machinery and Equipment \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	15 years
Furniture, fixtures and office equipment
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 2,969	2,969
Furniture, fixtures and office equipment \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Furniture, fixtures and office equipment \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	10 years
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 8,360	8,163
Estimated Useful Life (Years)	3 years
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 15,824	$ 10,892

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 67,243	$ 124,184
Short-term investments	95,203	79,932
Accounts receivable, net	9,823	4,739
Inventory	8,044	7,152
Prepaid expenses and other current assets	3,952	3,482
Total current assets	184,265	219,489
Property and equipment, net	41,453	36,612
Long-term investments	70,542	56,619
Other assets	12,058	8,441
Total assets	308,318	321,161
Current liabilities:
Accounts payable	8,702	6,956
Accrued expenses and other current liabilities	27,131	27,419
Financing liability — current	9,410	6,977
Deferred revenue — current	1,307	827
Recognized loss on purchase commitments — current	6,944	6,170
Total current liabilities	53,494	48,349
Senior convertible notes	224,307	223,944
Midcap credit facility	38,939	38,833
Promissory notes	18,425	18,425
Accrued interest — promissory notes	520	404
Financing liability — long term	93,463	93,525
Recognized loss on purchase commitments — long term	72,400	76,659
Operating lease liability	826	1,040
Deferred revenue — long term	26,116	19,543
Milestone rights liability	4,838	4,838
Deposits from customer	7,054	4,950
Total liabilities	540,382	530,510
Commitments and contingencies (Note 13)
Stockholders' deficit:
Undesignated preferred stock, $0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of March 31, 2022 and December 31, 2021
Common stock, $0.01 par value - 400,000,000 shares authorized, 252,413,434 and 251,477,562 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	2,524	2,515
Additional paid-in capital	2,922,555	2,918,205
Accumulated other comprehensive loss	(1,076)
Accumulated deficit	(3,156,067)	(3,130,069)
Total stockholders' deficit	(232,064)	(209,349)
Total liabilities and stockholders' deficit	$ 308,318	$ 321,161

Fair Value of Financial Instruments - Fair Value of Financial Instruments (Detail) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
MidCap Credit Facility
Financial liabilities:
Financial liabilities fair value	$ 40.7	$ 40.8
Senior Convertible Notes
Financial liabilities:
Financial liabilities fair value	221.6	237.5
Mann Group Convertible Notes
Financial liabilities:
Financial liabilities fair value	33.6	37.8
Milestone Rights Liability
Financial liabilities:
Financial liabilities fair value	17.1	18.1
Carrying Value \| MidCap Credit Facility
Financial liabilities:
Financial liabilities fair value	38.9	38.8
Carrying Value \| Senior Convertible Notes
Financial liabilities:
Financial liabilities fair value	224.3	223.9
Carrying Value \| Mann Group Convertible Notes
Financial liabilities:
Financial liabilities fair value	18.4	18.4
Carrying Value \| Milestone Rights Liability
Financial liabilities:
Financial liabilities fair value	5.9	5.9
Estimate of Fair Value Measurement \| Fair Value, Inputs, Level 3 \| MidCap Credit Facility
Financial liabilities:
Financial liabilities fair value	40.7	40.8
Estimate of Fair Value Measurement \| Senior Convertible Notes \| Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	221.6	237.5
Estimate of Fair Value Measurement \| Mann Group Convertible Notes \| Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	33.6	37.8
Estimate of Fair Value Measurement \| Milestone Rights Liability \| Fair Value, Inputs, Level 3
Financial liabilities:
Financial liabilities fair value	$ 17.1	$ 18.1

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2022

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

The following tables set forth the fair value of the Company’s financial instruments (Level 3 in the fair value hierarchy) (in millions):

	March 31, 2022
	Carrying Value		Significant Unobservable Inputs (Level 3)		Fair Value
Financial liabilities:
Senior convertible notes⁽¹⁾	$	224.3	$	221.6	$	221.6
MidCap credit facility⁽²⁾		38.9		40.7		40.7
Mann Group convertible notes⁽³⁾		18.4		33.6		33.6
Milestone rights⁽⁴⁾		5.9		17.1		17.1

_________________________

(1)

Fair value determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 12%, volatility of 83.6% and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or – 2% would result in a fair value of $211.1 million and $233.1 million, respectively.

(2)	Fair value determined by applying a discounted cash flow analysis with a hypothetical yield of 10%. A change in yield of + or – 2% would result in a fair value of $39.0 million and $42.4 million, respectively.

(3)

The fair value assessed as of March 31, 2022 was determined by applying a discounted cash flow analysis with a hypothetical yield of 12% and volatility of 84.2% to the straight note and a binomial option pricing model for the value of the conversion feature. A change in yield of + or – 2% would result in a fair value of $32.8 million and $34.6 million, respectively.

(4)	Fair value determined by applying a Monte Carlo simulation.

	December 31, 2021
	Carrying Value		Significant Unobservable Inputs (Level 3)		Fair Value
Financial liabilities:
Senior convertible notes⁽¹⁾	$	223.9	$	237.5	$	237.5
MidCap credit facility⁽²⁾		38.8		40.8		40.8
Mann Group convertible notes⁽³⁾		18.4		37.8		37.8
Milestone rights⁽⁴⁾		5.9		18.1		18.1

_________________________

(1)

Fair value determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 12%, volatility of 90% and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or – 2% would result in a fair value of $226.6 million and $249.4 million, respectively.

(2)	Fair value determined by applying a discounted cash flow analysis with a hypothetical yield of 10%. A change in yield of + or – 2% would result in a fair value of $39.1 million and $42.7 million, respectively.

(3)

The April 2021 amendment to the Mann Group convertible note resulted in a substantial premium of $22.1 million based on the fair value post modification which was recognized as additional paid-in capital in the condensed consolidated balance sheet as of December 31, 2021. The accounting for the $22.1 million loss on extinguishment did not result in a change in the financial position of the Company. The fair value assessed as of December 31, 2021 was determined by applying a discounted cash flow analysis with a hypothetical yield of 12% and volatility of 85% to the straight note and a binomial option pricing model for the value of the conversion feature. A change in yield of + or – 2% would result in a fair value of $36.9 million and $38.8 million, respectively.

(4)	Fair value determined by applying a Monte Carlo simulation.

Borrowings - Senior Convertible Notes - Additional Information (Detail)		1 Months Ended		3 Months Ended
	Mar. 04, 2021 USD ($) d $ / shares	Apr. 30, 2021	Aug. 31, 2019	Mar. 31, 2022 USD ($) d $ / shares	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($) $ / shares	Mar. 15, 2021 USD ($)
Debt Instrument [Line Items]
Principal amount				$ 288,400,000
Maturity date		Dec. 31, 2025	Nov. 03, 2024
Common stock, par value \| $ / shares				$ 0.01		$ 0.01
Proceeds from offering after deducting initial purchasers discounts and commissions and estimated offering expenses payable					$ 230,000,000
Senior Convertible Notes
Debt Instrument [Line Items]
Principal amount				$ 230,000,000.0		$ 230,000,000.0
Maturity date				Mar. 01, 2026
Annual interest rate				2.50%
Common stock, par value \| $ / shares				$ 0.01
Number of trading days \| d	20			20
Consecutive trading days \| d	30			30
Conversion price percentage	130.00%			130.00%
Principal amount per share \| $ / shares	$ 1,000			$ 1,000
Measurement period percentage				98.00%
Conversion price \| $ / shares	$ 5.21			$ 5.21
Initial conversion price of premium percentage	30.00%
No of convertible shares	191.8281
Redemption period start date	Mar. 06, 2024
Redemption price percentage	100.00%
Sinking fund	$ 0
Debt instrument redemption description				The Company may redeem for cash all or any portion of the Senior convertible notes, at its option, on or after March 6, 2024 and prior to the 36th scheduled trading day immediately preceding the maturity date, if the last reported sale price of common stock has been at least 130% of the conversion price for the Senior convertible notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Senior convertible notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company elects to redeem less than all of the outstanding Senior convertible notes, at least $75.0 million aggregate principal amount of Senior convertible notes must be outstanding and not subject to redemption as of the relevant redemption notice date. No sinking fund is provided for the Senior convertible notes.
Percentage of repurchase price	100.00%
Debt default, description				If certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries) occur, 100% of the principal of and accrued and unpaid interest on the Senior convertible notes will automatically become due and payable. If an event of default with respect to the Senior convertible notes, other than certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries), occurs and is continuing, the trustee, by notice to the Company, or the holders of at least 25% in principal amount of the outstanding Senior convertible notes by notice to the Company and the trustee, may, and the trustee at the request of such holders shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the Senior convertible notes to be due and payable. Notwithstanding the foregoing, the Indenture provides that, to the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 365 days after the occurrence of such an event of default consist exclusively of the right to receive additional interest on the Senior convertible notes as set forth in the Indenture
Proceeds from offering after deducting initial purchasers discounts and commissions and estimated offering expenses payable	$ 222,700,000
Unamortized debt issuance cost				$ 5,700,000
Senior Convertible Notes \| Minimum
Debt Instrument [Line Items]
Outstanding principal amount redeemed	75,000,000.0
Senior Convertible Notes \| Private Placement
Debt Instrument [Line Items]
Principal amount	$ 200,000,000.0						$ 30,000,000.0

Stock-Based Compensation Expense - Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock compensation expense	$ 2,806	$ 1,935
RSUs and Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock compensation expense	2,644	1,826
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock compensation expense	$ 162	$ 109

Commitments and Contingencies

3 Months Ended

Mar. 31, 2022

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

13. Commitments and Contingencies

Guarantees and Indemnifications — In the ordinary course of its business, the Company makes certain indemnities, commitments and guarantees under which it may be required to make payments in relation to certain transactions. The Company, as permitted under Delaware law and in accordance with its Bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. The Company has not recorded any liability for these indemnities in the condensed consolidated balance sheets. However, the Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable and the amount can be reasonably estimated. No such losses have been recorded to date.

Litigation — The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. As of March 31, 2022, the Company believes that the final disposition of such matters will not have a material adverse effect on the financial position, results of operations or cash flows of the Company and no accrual has been recorded. The Company maintains liability insurance coverage to protect the Company’s assets from losses arising out of or involving activities associated with ongoing and

normal business operations. The Company records a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company’s policy is to accrue for legal expenses in connection with legal proceedings and claims as they are incurred.

Contingencies — In July 2013, the Company entered into the Milestone Rights Agreement with the Original Milestone Purchasers, pursuant to which the Company granted the Milestone Rights to receive payments up to $90.0 million upon the occurrence of specified strategic and sales milestones, $65.0 million of which remains payable to the Milestone Purchasers upon achievement of such milestones (see Note 7 – Borrowings). The fair value of the Milestone Rights is recorded in the condensed consolidated balance sheet, including $1.1 million in accrued expenses and other current liabilities and $4.8 million in milestone rights liability.

Sale-Leaseback Transaction— On November 8, 2021, the Company sold the Property to the Purchaser for a sales price of $102.3 million, subject to terms and the conditions contained in a purchase and sale agreement.

Effective with the closing of the Sale-Leaseback Transaction, the Company and the Purchaser entered into a lease agreement (the “Lease”), pursuant to which the Company leased the Property from the Purchaser for an initial term of 20 years, with four renewal options of five years each. The total annual rent under the Lease starts at approximately $9.5 million per year, subject to a 50% rent abatement during the first year of the Lease, and will increase annually by (i) 2.5% in the second through fifth year of the Lease and (ii) 3% in the sixth and each subsequent year of the Lease, including any renewal term. The Company is responsible for payment of operating expenses, property taxes and insurance for the Property. The Purchaser will hold a security deposit of $2.0 million during the Lease term. Pursuant to the terms of the Lease, the Company has four options to repurchase the Property, in 2026, 2031, 2036 and 2041, for the greater of (i) $102.3 million and (ii) the fair market value of the Property.

Effective with the closing of the Sale-Leaseback Transaction, the Company and the Purchaser also entered into a right of first refusal agreement (the “ROFR”), pursuant to which the Company has a right to re-purchase the Property from the Purchaser in accordance with terms and conditions set forth in the ROFR. Specifically, if the Purchaser receives, and is willing to accept, a bona fide purchase offer for the Property from a third-party purchaser, the Company has certain rights of first refusal to purchase the Property on the same material terms as proposed in such bona fide purchase offer.

As of March 31, 2022, the related financing liability was $102.9 million, which was recognized in our condensed consolidated balance sheet as $93.5 million of financing liability — long-term and $9.4 million of financing liability — short-term. As of December 31, 2021, the related financing liability was $100.5 million, which was recognized in our condensed consolidated balance sheet as $93.5 million of financing liability — long-term and $7.0 million of financing liability — short-term.

Financing liability information is as follows (in thousands):

	March 31, 2022			December 31, 2021
Weighted average remaining lease term (in years)	19.6				19.8
Weighted average discount rate		9.0	%		9.0	%

Three Months Ended

March 31,

2022

2021

Interest expense on financing liability

2,371

—

Financing liability payments as of March 31, 2022 was as follows (in thousands):

	March 31, 2022			December 31, 2021
2022⁽¹⁾	$	6,373		$	6,373
2023		9,778			9,778
2024		10,023			10,023
2025		10,274			10,274
2026		10,539			10,539
Thereafter		199,091			199,091
Total		246,078			246,078
Interest expense		(140,165	)		(142,485	)
Debt issuance costs		(3,040	)		(3,091	)
Total financing liability	$	102,873		$	100,502

_________________________

⁽¹⁾	2022 includes amortization of the rent abatement.

Commitments — In July 2014, the Company entered into the Insulin Supply Agreement with Amphastar pursuant to which Amphastar manufactures for and supplies to the Company certain quantities of recombinant human insulin for use in Afrezza. Under the terms of the Insulin Supply Agreement, Amphastar is responsible for manufacturing the insulin in accordance with the Company’s specifications and agreed-upon quality standards.

	March 31, 2022			March 31, 2021
2021	€		—	€	7.0 million
2022	€	4.1 million		€	8.5 million
2023	€	8.8 million		€	10.9 million
2024	€	14.6 million		€	14.6 million
2025	€	15.5 million		€	15.5 million
2026	€	19.4 million		€	19.4 million
2027	€	9.2 million		€		—

Pursuant to the amendment, the term of the Insulin Supply Agreement expires on December 31, 2027, unless terminated earlier, and can be renewed for additional, successive two-year terms upon 12 months’ written notice given prior to the end of the initial term or any additional two-year term. The Company and Amphastar each have normal and customary termination rights, including termination for a material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, the Company may terminate the Insulin Supply Agreement upon two years’ prior written notice to Amphastar without cause or upon 30 days’ prior written notice to Amphastar if a controlling regulatory authority withdraws approval for Afrezza, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Insulin Supply Agreement require the Company to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination.

Vehicle Leases – During the second quarter of 2018, the Company entered into a master lease agreement with Enterprise Fleet Management Inc. During 2021, 85 vehicles were retired and replaced, resulting in a fleet size of 89 vehicles. The Company received proceeds for the gain on the retired vehicles residual value in the amount of $0.5 million, which is included as a reduction to our lease expense. The revised monthly payment inclusive of maintenance fees, insurance and taxes is approximately $0.1 million and the additional right of use asset and lease obligation is approximately $1.4 million in the condensed consolidated balance sheets. The lease expense is included in selling, general and administrative expenses in the condensed consolidated statements of operations.

Office Leases — In May 2017, the Company executed an office lease with Russell Ranch Road II LLC for the Company’s corporate offices in Westlake Village, California. The office lease commenced in August 2017. The Company agreed to pay initial monthly lease payments of $40,951, subject to 3% annual increases, plus the estimated cost of maintaining the property and common areas by the landlord, with a five-month concession from October 2017 through February 2018. The lease also provides for allowances for tenant alterations and maintenance. The lease expense is included in selling, general and administrative expenses in the condensed consolidated statements of operations.

In November 2017, the Company executed an office lease with Russell Ranch Road II LLC to expand the office space for the Company’s corporate offices in Westlake Village, California. The office lease commenced in October 2018. The Company agreed to pay initial monthly lease payments of $35,969, subject to a 3% annual increase, plus the estimated operating cost of maintaining the property by the landlord, which are allocable based an annual assessment made by the landlord. In addition, the Company received reimbursement from the landlord of $56,325 for tenant improvements and was not required to pay a first-year common area maintenance fee.

Subsequent to March 31, 2022, the Company renewed its office lease with Russell Ranch Road II LLC. Pursuant to the renewal, the Company will pay initial monthly payments of $79,543, subject to 3% annual increases, plus the estimated cost of maintaining the property and common areas by the landlord. The Company will receive a fourteen-month concession from the lease commencement period of February 2023 through March 2024. The lease provides the Company with a 66 month renewal option.

Lease information is as follows (in thousands):

	Three Months Ended March 31,
	2022		2021
Operating lease costs	$	288	$	350
Variable lease costs		86		111
Cash paid		442		461

	March 31, 2022			December 31, 2021
Weighted average remaining lease term (in years)		2.4			2.6
Weighted average discount rate		7.3	%		7.3	%

Future minimum office and vehicle lease payments as of March 31, 2022 and December 31, 2021, are as follows (in thousands):

	March 31, 2022		December 31, 2021
2022	$	1,060	$	1,444
2023		463		497
2024		375		409
2025		313		311
Total	$	2,211	$	2,661

Accounts Receivable

3 Months Ended

Mar. 31, 2022

Receivables [Abstract]

Accounts Receivable

3. Accounts Receivable

Accounts receivable, net consists of the following (in thousands):

	March 31, 2022			December 31, 2021
Accounts receivable – commercial
Accounts receivable, gross	$	8,656		$	7,939
Wholesaler distribution fees and prompt pay discounts		(1,201	)		(1,696	)
Reserve for returns		(3,089	)		(2,797	)
Total accounts receivable – commercial, net		4,366			3,446
Accounts receivable – collaborations and services
Accounts receivable, gross		6,224			2,060
Allowance for doubtful accounts		(767	)		(767	)
Total accounts receivable – collaborations and services, net		5,457			1,293
Total accounts receivable, net	$	9,823		$	4,739

As of March 31, 2022 and December 31, 2021, the allowance for doubtful accounts for accounts receivable – commercial was de minimis. The Company had three wholesale distributors representing approximately 74% of commercial accounts receivable as of March 31, 2022 and approximately 69% of gross sales for the three months ended March 31, 2022.

As of March 31, 2022, the allowance for credit losses for accounts receivable – collaborations and services of $0.8 million was related to $0.8 million of accounts receivable for Vertice Pharma for the co-promotion of Thyquidity. The Company had one collaboration partner, United Therapeutics, that comprised 100% of the collaboration and services net accounts receivable as of March 31, 2022 and approximately 94% of gross revenue from collaborations and services for the three months ended March 31, 2022.

Schedule of Accounts Receivable, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Accounts Receivable [Line Items]
Total accounts receivable, net	$ 9,823	$ 4,739
Allowance for doubtful accounts	(800)
Commercial product sales
Accounts Receivable [Line Items]
Accounts receivable, gross	8,656	7,939
Wholesaler distribution fees and prompt pay discounts	(1,201)	(1,696)
Reserve for returns	(3,089)	(2,797)
Total accounts receivable, net	4,366	3,446
Collaborations and services
Accounts Receivable [Line Items]
Accounts receivable, gross	6,224	2,060
Total accounts receivable, net	5,457	1,293
Allowance for doubtful accounts	$ (767)	$ (767)

Property and Equipment

3 Months Ended

Mar. 31, 2022

Property Plant And Equipment [Abstract]

Property and Equipment

5. Property and Equipment

Property and equipment consists of the following (in thousands):

	Estimated Useful
	Life (Years)		March 31, 2022				December 31, 2021
Land		—	$	875			$	875
Buildings	39-40			17,389				17,389
Building improvements	5-40			38,651				38,651
Machinery and equipment	3-15			55,294				55,334
Furniture, fixtures and office equipment	5-10			2,969				2,969
Computer equipment and software		3		8,360				8,163
Construction in progress		—		15,824		⁽¹⁾		10,892
				139,362				134,273
Less accumulated depreciation				(97,909	)			(97,661	)
Total property and equipment, net			$	41,453			$	36,612

____________________

(1)

Depreciation expense related to property and equipment for the three months ended March 31, 2022 and 2021 was as follows (in thousands):

Three Months Ended

March 31,

2022

2021

Depreciation Expense

599

460

On November 8, 2021, the Company sold certain land, building and improvements located in Danbury, CT (the “Property”) to an affiliate of Creative Manufacturing Properties (the “Purchaser”) for a sales price of $102.3 million, subject to terms and the conditions contained in a purchase and sale agreement. Effective with the closing of this transaction, the Company entered into a 20-year lease agreement with the Purchaser (the “Sale-Leaseback Transaction”). The sale of the Property and subsequent lease did not result in the transfer of control of the Property to the Purchaser; therefore, the Sale-Leaseback Transaction qualified as a failed sale leaseback transaction whereby the lease is accounted for as a finance lease and the Property remains as a long-lived asset of the Company and is depreciated at its remaining useful life of 20 years or less. See Note 13 – Commitments and Contingencies.

Collaboration, Licensing and Other Arrangements - Schedule of Effect of Modification on Transaction Price (Detail) - Collaboration and License Agreement - United Therapeutics Corporation
$ in Millions

Oct. 31, 2021

USD ($)

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Anticipated Cash Flow

$ 463.5

^[1]

R&D Services and License | Over Time

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Progress Measure

Ratably

^[2]

Recognition Period

Aug 2021 - Oct 2021

^[2],[3]

Next-Gen R&D Services | Over Time

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Anticipated Revenue Allocation

$ 4.8

^[4],[5]

Progress Measure

Input

^[4]

Recognition Period

% of completion of costs

^[4],[6]

Manufacturing Services | Point In Time

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Anticipated Revenue Allocation

$ 458.7

^[5],[7]

Recognition Period

Transfer of control

^[7],[8]

[1]	The total anticipated cash flow includes a transaction price of $64.3 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $399.2 million for future supply of Tyvaso DPI over the remaining term of the CSA.
[2]	The license for the Company’s IP was considered to be interdependent with the development activities to support approval of Tyvaso DPI. A sales-based royalty is promised in exchange for the IP license; therefore, the royalties associated with the license are excluded from the determination of the transaction price and the Company will recognize revenue as the sale of Tyvaso DPI to a patient occurs.
[3]	Represents the period when the revenue for the R&D Services performance obligation was recognized.
[4]	The standalone selling price (“SSP”) for the Next-Gen R&D Services performance obligation was based on industry ratios as well as the Company’s historical R&D projects. The transaction price for the Next-Gen R&D Services was based on fixed consideration which was allocated between performance obligations as discussed in note (2) above.
[5]	Allocation is based on management’s assessment of the stand-alone selling price of each performance obligation.
[6]	The Next-Gen R&D Services performance obligation will be satisfied over time using the input method based on the costs incurred to date as a percentage of the total estimated costs to fulfill the contract. Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer.
[7]	Pre-production activities under the CSA, such as facility expansion services and certain other administrative services, were considered bundled services that are part of the Company’s Manufacturing Services performance obligation, given the nature of the Company’s contractual responsibilities and ASC 606 requirements.
[8]	The Manufacturing Services performance obligation will be recognized as control of manufactured products is transferred to UT. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of transaction price includes a material right related to manufacturing services in the amount of $144.5 million. The total anticipated cash flow is based on the Company’s estimated production and the ultimate cash flows may vary as manufacturing purchase orders are received.

Property and Equipment - Additional Information (Detail) - 1 Casper, LLC $ in Millions	Nov. 08, 2021 USD ($)
Property Plant And Equipment [Line Items]
Sale price	$ 102.3
Sale leaseback transaction, lease agreement period.	20 years
Sale leaseback transaction, date	November 8, 2021

Description of Business and Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash

	March 31, 2022		December 31, 2021		March 31, 2021
Cash and cash equivalents	$	67,243	$	124,184	$	247,833
Restricted cash		—		—		158
Total cash, cash equivalents, and restricted cash	$	67,243	$	124,184	$	247,991

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (25,998)	$ (12,916)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	2,806	1,935
Interest expense on financing liability	2,371
Depreciation and amortization	1,324	655
Amortization of right-of-use assets	289	309
Interest expense on promissory notes	116	1,028
Gain on foreign currency translation	(1,983)	(3,838)
Changes in operating assets and liabilities:
Accounts receivable, net	(4,829)	645
Inventory	(892)	(77)
Prepaid expenses and other current assets	(470)	356
Other assets	(320)	(97)
Accounts payable	1,745	1,124
Accrued expenses and other current liabilities	510	8,288
Deferred revenue	7,053	(7,431)
Operating lease liabilities	(572)	(333)
Recognized loss on purchase commitments	(1,502)	(2,379)
Customer deposits	2,104
Net cash used in operating activities	(18,248)	(12,731)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of debt securities	(55,988)	(30,442)
Proceeds from maturity of debt securities	26,538
Purchase of property and equipment	(5,056)	(976)
Purchase of available-for-sale securities	(5,000)
Net cash used in investing activities	(39,506)	(31,418)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the Senior convertible notes		230,000
Issuance costs associated with Senior convertible notes		(7,268)
Payment of employment taxes related to vested restricted stock units and exercise of stock options	129	397
Proceeds from market price stock purchase plan	684	0
Net cash provided by financing activities	813	224,977
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(56,941)	180,828
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	124,184	67,163
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	67,243	247,991
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Interest paid in cash	3,600	1,094
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Reclassification of investments from long-term to current	14,813
Common stock issuance to settle employee stock purchase plan liability	740	390
Non-cash construction in progress and property and equipment	$ 383	124
Reclassification of the PPP Loan from current to long-term		609
2024 Convertible Notes
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Payment of 2024 convertible notes through common stock issuance		5,000
Payment of interest through common stock issuance		143
Mann Group
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Payment of convertible notes through common stock issuance		9,573
Payment of interest through common stock issuance		427
At The Market Issuance
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from at-the-market offering		1,886
Issuance costs associated with at-the-market offering		$ (38)

Borrowings

3 Months Ended

Mar. 31, 2022

Debt Disclosure [Abstract]

Borrowings

7. Borrowings

Carrying amount of borrowings consist of the following (in thousands):

	March 31, 2022		December 31, 2021
Senior convertible notes	$	224,307	$	223,944
MidCap credit facility		38,939		38,833
Mann Group promissory notes		18,425		18,425
Total debt — net carrying amount	$	281,671	$	281,202

The following table provides a summary of the Company’s debt and key terms:

Amount Due

Terms

March 31, 2022

December 31, 2021

Annual Interest Rate

Maturity Date

Conversion Price

Senior convertible notes

$230.0 million

2.50%

March 2026

$5.21

per share

MidCap credit facility⁽¹⁾

$40.0 million

one-month

LIBOR (1% floor)

plus 6.25%

)

August 2025

)

N/A

Mann Group convertible note

$18.4 million (plus $0.5 million accrued interest paid-in-kind)

$18.4 million (plus $0.4 million accrued interest paid-in-kind)

2.50%

)

December 2025

)

$2.50

per share

______________________________________________

(1)	In April 2021, the Company prepaid $10.0 million principal balance and amended the MidCap credit facility. The interest rate prior to the amendment was one-month LIBOR (2% floor) plus 6.75% and the maturity date was in August 2024.

(2)	In April 2021, the Mann Group convertible note was amended. The interest rate prior to the amendment was 7.00% and the maturity date was in November 2024.

The maturities of the Company’s borrowings as of March 31, 2022 are as follows (in thousands):

	Amounts
2022	$	—
2023		6,667
2024		20,000
2025		31,758
Thereafter		230,000
Total principal payments		288,425
Unamortized discount		(1,061	)
Debt issuance costs		(5,693	)
Total debt — net carrying amount	$	281,671

Senior convertible notes – On March 4, 2021, the Company issued $200.0 million aggregate principal amount of Senior convertible notes in a private offering. Pursuant to an option to purchase additional senior convertible notes in the purchase agreement between the Company and the initial purchasers of the Senior convertible notes, the Company issued an additional $30.0 million aggregate principal amount of Senior convertible notes on March 15, 2021. The Senior convertible notes were issued pursuant to an indenture, dated March 4, 2021 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee.

The Senior convertible notes are general unsecured obligations of the Company and will mature on March 1, 2026, unless earlier converted, redeemed or repurchased. The Senior convertible notes will bear cash interest from March 4, 2021 at an annual rate of 2.50% payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2021. The Senior convertible notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding December 1, 2025, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock, par value $0.01 per share, for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the Senior convertible notes on each applicable trading day; (2) during the five business day period after any

ten consecutive trading day period in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Senior convertible notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on each such trading day; (3) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Senior convertible notes called (or deemed called) for redemption; or (4) upon the occurrence of specified corporate events as set forth in the Indenture. On or after December 1, 2025 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture.

The initial conversion rate is 191.8281 shares of common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.21 per share of common stock). The initial conversion price of the Senior convertible notes represents a premium of approximately 30% to the last reported sale price of the common stock on the Nasdaq Global Market on March 1, 2021. The conversion rate for the Senior convertible notes is subject to adjustment under certain circumstances in accordance with the terms of the Indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date of the Senior convertible notes or if the Company delivers a notice of redemption in respect of the Senior convertible notes, the Company will, in certain circumstances, increase the conversion rate of the Senior convertible notes for a holder who elects to convert its Senior convertible notes in connection with such a corporate event or convert its Notes called for redemption during the related redemption period (as defined in the Indenture), as the case may be.

The Company may not redeem the Senior convertible notes prior to March 6, 2024. The Company may redeem for cash all or any portion of the Senior convertible notes, at its option, on or after March 6, 2024 and prior to the 36th scheduled trading day immediately preceding the maturity date, if the last reported sale price of common stock has been at least 130% of the conversion price for the Senior convertible notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Senior convertible notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company elects to redeem less than all of the outstanding Senior convertible notes, at least $75.0 million aggregate principal amount of Senior convertible notes must be outstanding and not subject to redemption as of the relevant redemption notice date. No sinking fund is provided for the Senior convertible notes.

If the Company undergoes a fundamental change (as defined in the Indenture), then, subject to certain conditions and except as described in the Indenture, holders may require the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Senior convertible notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The Indenture includes customary covenants and sets forth certain events of default after which the Senior convertible notes may be declared immediately due and payable.

If certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries) occur, 100% of the principal of and accrued and unpaid interest on the Senior convertible notes will automatically become due and payable. If an event of default with respect to the Senior convertible notes, other than certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries), occurs and is continuing, the trustee, by notice to the Company, or the holders of at least 25% in principal amount of the outstanding Senior convertible notes by notice to the Company and the trustee, may, and the trustee at the request of such holders shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the Senior convertible notes to be due and payable. Notwithstanding the foregoing, the Indenture provides that, to the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 365 days after the occurrence of such an event of default consist exclusively of the right to receive additional interest on the Senior convertible notes as set forth in the Indenture.

The Indenture provides that the Company shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of the consolidated properties and assets of the Company and its subsidiaries, taken as a whole, to, another person (other than any such sale, conveyance, transfer or lease to one or more of the Company’s direct or indirect wholly owned subsidiaries), unless: (i) the resulting, surviving or transferee person (if not the Company) is a corporation organized and existing under the laws of the United States of America, any State thereof or the District of Columbia, and such corporation (if not the Company) expressly assumes by supplemental indenture all of the Company’s obligations under the Senior convertible notes and the Indenture; and (ii) immediately after giving effect to such transaction, no default or event of default has occurred and is continuing under the Indenture.

The Company’s net proceeds from the offering were approximately $222.7 million, after deducting the initial purchasers’ discounts and commissions and the estimated offering expenses payable by the Company. As of March 31, 2022, the unamortized debt issuance cost was $5.7 million.

MidCap credit facility — In August 2019, the Company entered into the MidCap credit facility and borrowed the first advance of $40.0 million (“Tranche 1”) in August 2019 and the second advance of $10.0 million (“Tranche 2”) in December 2020. In April 2021, $10.0 million was prepaid. Under the terms of the MidCap credit facility, a third advance of $60.0 million (“Tranche 3”) will be available to the Company between January 1, 2022 and June 30, 2022, subject to the satisfaction of certain milestone conditions associated with Tyvaso DPI^™ through the Company’s collaboration with United Therapeutics (see Note 8 – Collaboration, Licensing and Other Arrangements).

The MidCap credit facility has been amended several times, most recently in April 2021, pursuant to which the parties agreed to, among other things, (i) increase the amount available under the third advance from $25.0 million to $60.0 million and extend the date through which the third advance is available to June 30, 2022, (ii) amend the conditions to the third advance of $60.0 million being available to draw, including certain milestone conditions associated with Tyvaso DPI, (iii) remove the Company’s obligation to issue a warrant to purchase shares of the Company’s common stock upon drawing down the third advance, (iv) extend the interest-only period until September 1, 2023 and extend the maturity date until August 1, 2025, (v) amend the financial covenant relating to trailing 12 month minimum Afrezza net revenue, (vi) decrease the minimum cash covenant, (vii) decrease the interest rate on any amounts outstanding, now or in the future, under the MidCap credit facility, (viii) permit the Company to make certain acquisitions, subject to requirements, and (ix) permit the Company to make investments of up to an additional $9.0 million so long as the Company has $90.0 million or more of unrestricted cash and short-term investments following such investment. Concurrent with entering into this amendment, the Company made a $10.0 million principal prepayment against outstanding term loans under the MidCap credit facility and paid a related $1.0 million exit fee in lieu of the unaccrued portion of the original exit fee and prepayment penalties that would otherwise have been due with respect to the partial prepayment.

The prepayment penalty of $1.0 million related to the payment of $10.0 million was capitalized and will be amortized over the remaining life of the debt. As of March 31, 2022, the unamortized debt discount was $0.3 million and the unamortized prepayment penalty was $0.7 million.

Tranche 1, Tranche 2 and, if borrowed, Tranche 3, each accrue interest at an annual rate equal to the lesser of (i) 8.25% and (ii) the one-month LIBOR (subject to a one-month LIBOR floor of 1.00%) plus 6.25%. Interest on each term loan advance is due and payable monthly in arrears. Principal on each term loan advance under Tranche 1, Tranche 2 and, if applicable, Tranche 3 is payable in 24 equal monthly installments beginning September 1, 2023, until paid in full on August 1, 2025. The Company has the option to prepay its existing term loans, in whole or in part, subject to early termination fees in an amount equal to 3.00% of principal prepaid if prepayment occurs on or prior to April 22, 2022; 2.00% of principal prepaid if prepayment occurs on or after April 23, 2022 through and including April 22, 2023; and 1.00% of principal prepaid if prepayment occurs on or after April 23, 2023 through the maturity date. Tranche 3 will be subject to a similar scheme of early termination fees measured from the anniversary of the funding date for such tranche, if ever.

The Company’s obligations under the MidCap credit facility are secured by a security interest on substantially all of its assets, including intellectual property.

The MidCap credit facility, as amended, contains customary affirmative covenants and customary negative covenants limiting the Company’s ability and the ability of the Company’s subsidiaries to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions. The Company must also comply with a financial covenant relating to trailing twelve month minimum Afrezza net revenue, tested on a monthly basis, unless the Company has $90.0 million or more of unrestricted cash and short-term investments. The Company is also subject to a minimum cash covenant of $10.0 million at all times; however, this covenant will be eliminated in the event that Tyvaso DPI is approved by the FDA. As of March 31, 2022, the Company was in compliance with the financial and minimum cash covenants.

The MidCap credit facility also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, listing of the Company’s common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, the agent and the lenders may declare all or a portion of the Company’s outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the MidCap credit facility. During the existence of an event of default, interest on the term loans could be increased by 2.00%.

Mann Group promissory notes — In August 2019, the Company issued a $35.0 million note that is convertible into shares of the Company’s common stock at $2.50 per share (the “Mann Group convertible note”) and issued a non-convertible note to Mann Group in an aggregate principal amount of $35.1 million (the “Mann Group non-convertible note” and, together with the Mann Group convertible note, the “Mann Group promissory notes”) as part of a restructuring of its then existing indebtedness to Mann Group.

The Mann Group promissory notes originally accrued interest at the rate of 7.00% per year on the principal amount, payable quarterly in arrears on the first day of each calendar quarter beginning October 1, 2019. In April 2021, the Company repaid the entire principal amount of $35.1 million outstanding under the Mann Group non-convertible note, together with all accrued and unpaid interest thereon. On the same date, the Company and Mann Group amended the Mann Group convertible note, pursuant to which the parties agreed to (i) reduce the interest rate from 7.0% to 2.5% effective on April 22, 2021, and (ii) extend the maturity date from November 3, 2024 to December 31, 2025.

The amendment to the Mann Group convertible note resulted in a debt extinguishment with a substantial premium based on the fair value post extinguishment. The fair value in excess of the face amount of $18.4 million contributed to a loss on extinguishment of $22.1 million in the consolidated statement of operations for the year ended December 31, 2021 and resulted in a corresponding debt premium of $22.1 million which was recognized as additional paid-in capital in the consolidated balance sheet as of December 31, 2021. The accounting for the $22.1 million loss on extinguishment did not result in a change in the financial position of the Company. The Company wrote off a de minimis amount of debt issuance cost.

The principal and any accrued and unpaid interest under the Mann Group convertible note may be converted, at the option of Mann Group, at any time on or prior to the close of business on the business day immediately preceding the stated maturity date, into shares of the Company’s common stock at a conversion rate of 400 shares per $1,000 of principal and/or accrued and unpaid interest, which is equal to a conversion price of $2.50 per share. The conversion rate will be subject to adjustment under certain circumstances described in the Mann Group convertible note. Interest on the convertible note will be payable in kind by adding the amount thereof to the principal amount; provided that with respect to interest accruing from and after January 1, 2021, the Company may, at its option, elect to pay any such interest on any interest payment date, if certain conditions are met, in shares of the Company’s common stock at a price per shall equal to the last reported sale price on the trading day immediately prior to the payment date.

During the year ended December 31, 2021, Mann Group converted $0.4 million of interest and $9.6 million of principal into 4,000,000 shares of common stock.

Amortization of debt discount and debt issuance cost related to all borrowings for the three months ended March 31, 2022 and 2021 were as follows (in thousands):

	Three Months Ended March 31,
	2022		2021
Amortization of debt discount	$	106	$	60
Amortization of debt issuance cost		363		124

Milestone Rights — As of March 31, 2022 and December 31, 2021, the remaining Milestone Rights liability balance was $5.9 million, which was based on initial fair value estimates calculated using the income approach and reduced by milestone achievement payments made. For each period, the $5.9 million liability consisted of a $1.1 million current liability which was presented as accrued expenses and other current liabilities and a $4.8 million long-term liability which was presented as milestone rights liability in our condensed consolidated balance sheets.

The Milestone Rights Agreement includes customary representations and warranties and covenants by the Company, including restrictions on transfers of intellectual property related to Afrezza. The Milestone Rights are subject to acceleration in the event the Company transfers its intellectual property related to Afrezza in violation of the terms of such agreement.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Borrowings - Schedule of Line of Credit Facility Debt and Key Terms (Detail) - USD ($)
$ / shares in Units, $ in Millions

3 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Mar. 04, 2021

Amount Due

$ 288.4

Senior Convertible Notes

$ 230.0

2.50%

2026-03

$ 5.21

Amount Due

^[1]

$ 40.0

40.0

MidCap Credit Facility | LIBOR

^[1]

2025-08

^[1]

6.25%

Mann Group | Convertible Promissory Note

^[1]

1.00%

Accrued interest paid-in-kind

Amount Due

$ 18.4

18.4

$ 0.5

$ 0.4

^[2]

2.50%

^[2]

2025-12

Conversion price

$ 2.50

[1]	In April 2021, the Company prepaid $10.0 million principal balance and amended the MidCap credit facility. The interest rate prior to the amendment was one-month LIBOR (2% floor) plus 6.75% and the maturity date was in August 2024.
[2]	In April 2021, the Mann Group convertible note was amended. The interest rate prior to the amendment was 7.00% and the maturity date was in November 2024.

Borrowings - MidCap Credit Facility - Additional Information (Detail)

1 Months Ended

3 Months Ended

12 Months Ended

Apr. 30, 2021

USD ($)

Installment

Dec. 31, 2020

Installment

Aug. 31, 2019

USD ($)

Installment

Mar. 31, 2022

USD ($)

Dec. 31, 2020

USD ($)

Mar. 31, 2021

USD ($)

Unamortized debt discount

Dec. 31, 2025

Nov. 03, 2024

$ 1,061,000

Debt instrument payment term description

Prepaid of borrowing

$ 10,000,000.0

Principal on each term loan advance under Tranche 1, Tranche 2 and, if applicable, Tranche 3 is payable in 24 equal monthly installments beginning September 1, 2023, until paid in full on August 1, 2025.

Debt instrument minimum unrestricted cash and short-term investments

$ 90,000,000.0

Principal prepayment against outstanding term loans

10,000,000.0

Original exit fee and prepayment penalties

1,000,000.0

Unamortized debt discount

$ 300,000

Debt Instrument unamortized prepayment penalty.

$ 700,000

Minimum cash covenant

$ 10,000,000.0

Interest on loans increased, percentage

2.00%

MidCap Credit Facility | On or After April 23, 2022 Through and Including April 22, 2023

Early termination fees, percentage

2.00%

MidCap Credit Facility | On or Prior to April 22, 2022

Early termination fees, percentage

3.00%

MidCap Credit Facility | On or After April 23, 2023 Through Maturity Date

Early termination fees, percentage

1.00%

MidCap Credit Facility | LIBOR

Tranche 1 | MidCap Credit Facility

^[1]

1.00%

Advance of borrowing

$ 40,000,000.0

Aug. 01, 2025

Debt payable number of equal monthly installments | Installment

8.25%

Line of credit facility principal payment start date

Sep. 01, 2023

Tranche 1 | MidCap Credit Facility | LIBOR

Interest rate (LIBOR)

6.25%

Tranche 2 | MidCap Credit Facility

1.00%

Advance of borrowing

$ 10,000,000.0

Aug. 01, 2025

Debt payable number of equal monthly installments | Installment

8.25%

Line of credit facility principal payment start date

Sep. 01, 2023

Tranche 2 | MidCap Credit Facility | LIBOR

Interest rate (LIBOR)

6.25%

Tranche 3 | MidCap Credit Facility

1.00%

Amount available under credit facility

$ 60,000,000.0

$ 25,000,000.0

Debt instrument advance available date

Jun. 30, 2022

Debt instrument extended interest-only date

Sep. 01, 2023

Debt instrument payment term description

Aug. 01, 2025

Maximum value of additional investment limit

$ 9,000,000.0

Debt instrument minimum unrestricted cash and short-term investments

$ 90,000,000.0

Debt payable number of equal monthly installments | Installment

8.25%

Line of credit facility principal payment start date

Sep. 01, 2023

Tranche 3 | MidCap Credit Facility | LIBOR

Interest rate (LIBOR)

6.25%

Fair Value of Financial Instruments

1.00%

[1]	In April 2021, the Company prepaid $10.0 million principal balance and amended the MidCap credit facility. The interest rate prior to the amendment was one-month LIBOR (2% floor) plus 6.75% and the maturity date was in August 2024.

Stock-Based Compensation - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2022 shares
Employees Awards \| RSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted awards	88,415

Commitments and Contingencies - Schedule of Financing Liability Lease Term and Discount Rate (Detail)	Mar. 31, 2022	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Weighted average remaining lease term (in years)	19 years 7 months 6 days	19 years 9 months 18 days
Weighted average discount rate	9.00%	9.00%

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2022

Fair Value Disclosures [Abstract]

9. Fair Value of Financial Instruments

The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. The Company uses the exit price method for estimating the fair value of loans for disclosure purposes. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy, as follows:

Level 1 — Quoted prices for identical instruments in active markets.

Level 3 — Significant inputs to the valuation model are unobservable.

The carrying amounts reported in the condensed consolidated financial statements for cash, accounts receivable, accounts payable, and accrued expenses and other current liabilities (excluding the Milestone Rights liability) approximate their fair value due to their relatively short maturities. The fair value of the cash equivalents, long- and short-term investments, MidCap credit facility, Mann Group promissory notes, 2024 convertible notes, Senior convertible notes, Milestone Rights liabilities and Financing liability are disclosed below.

Cash Equivalents and Restricted Cash— Cash equivalents consist of highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase that are readily convertible into cash. As of March 31, 2022 and December 31, 2021, the Company held $67.2 million and $124.2 million, respectively, of cash and cash equivalents.

Financial Liabilities — The following tables set forth the fair value of the Company’s financial instruments (Level 3 in the fair value hierarchy) (in millions):

	March 31, 2022
	Carrying Value		Significant Unobservable Inputs (Level 3)		Fair Value
Financial liabilities:
Senior convertible notes⁽¹⁾	$	224.3	$	221.6	$	221.6
MidCap credit facility⁽²⁾		38.9		40.7		40.7
Mann Group convertible notes⁽³⁾		18.4		33.6		33.6
Milestone rights⁽⁴⁾		5.9		17.1		17.1

_________________________

(1)

(2)	Fair value determined by applying a discounted cash flow analysis with a hypothetical yield of 10%. A change in yield of + or – 2% would result in a fair value of $39.0 million and $42.4 million, respectively.

(3)

(4)	Fair value determined by applying a Monte Carlo simulation.

	December 31, 2021
	Carrying Value		Significant Unobservable Inputs (Level 3)		Fair Value
Financial liabilities:
Senior convertible notes⁽¹⁾	$	223.9	$	237.5	$	237.5
MidCap credit facility⁽²⁾		38.8		40.8		40.8
Mann Group convertible notes⁽³⁾		18.4		37.8		37.8
Milestone rights⁽⁴⁾		5.9		18.1		18.1

_________________________

(1)

(2)	Fair value determined by applying a discounted cash flow analysis with a hypothetical yield of 10%. A change in yield of + or – 2% would result in a fair value of $39.1 million and $42.7 million, respectively.

(3)

(4)	Fair value determined by applying a Monte Carlo simulation.

Milestone Rights Liability — The fair value measurement of the Milestone Rights liability is sensitive to the discount rate and the timing of achievement of milestones. The Company utilized Monte-Carlo Simulation Method to simulate the Afrezza net sales under a neutral framework to estimate the payment. The Company then discounted the future expected payments at cost of debt with a term equal to the simulated time to payout based on cumulative sales.

Financing Liability — The Sale-Leaseback Transaction in November 2021 resulted in a financing liability which is included in our condensed consolidated balance sheets as a current financing liability of $9.4 million and a long-term financing liability of $93.5 million. The Company determined the fair value of the financing liability using level 3 inputs. As of March 31, 2021, the fair value was determined using a discounted cash flow analysis with a hypothetical yield of 9.0%. As of December 31, 2021, the Company evaluated the fair value of its financing liability and determined that the fair value approximated the carrying value.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Earnings Per Common Share ("EPS") - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Detail) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	73,384,218	70,472,100
Senior Convertible Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	44,120,463	44,120,463
Mann Group Convertible Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	7,370,000	7,370,000
Common Stock Options and PNQs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	10,335,424	11,321,734
RSUs and Market RSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	11,472,698	6,282,279
Employee Stock Purchase Plan
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	85,633	94,157
Warrants Associated with MidCap Credit Facility
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share		1,283,467

Inventories

3 Months Ended

Mar. 31, 2022

Inventory Disclosure [Abstract]

Inventories

4. Inventories

Inventories consist of the following (in thousands):

	March 31, 2022		December 31, 2021
Raw materials	$	3,201	$	2,703
Work-in-process		3,276		2,522
Finished goods		1,567		1,927
Total inventory	$	8,044	$	7,152

Work-in-process and finished goods as of March 31, 2022 and December 31, 2021 include conversion costs and exclude the cost of insulin. All insulin inventory on hand was written off and the projected loss on the purchase commitment contract to purchase future insulin was accrued as of the end of 2015. Raw materials inventory included $0.8 million of pre-launch inventory as of March 31, 2022 and December 31, 2021, which consisted of FDKP received in November 2019. The Company expects to receive FDA approval of the new source of FDKP in 2023.

The Company analyzed its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company also performed an assessment of projected sales and evaluated the lower of cost or net realizable value and the potential excess inventory on hand at March 31, 2022 and December 31, 2021. Inventory that was forecasted to become obsolete due to expiration as well as inventory that does not meet acceptable standards is recorded in costs of goods sold in the condensed consolidated statements of operations. There were no inventory write-offs for the three months ended March 31, 2022 or 2021.

Commitments and Contingencies - Summary of Financing Liability Costs (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($)
Commitments And Contingencies Disclosure [Abstract]
Interest expense on financing liability	$ 2,371

Borrowings - Summary of Carrying Amount of Principal Borrowings (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Senior convertible notes	$ 224,307	$ 223,944
Mann Group promissory notes	18,425	18,425
Total debt — net carrying amount	281,671	281,202
MidCap Credit Facility
Debt Instrument [Line Items]
Credit Facility	$ 38,939	$ 38,833

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

Schedule of Fair Value of Cash Equivalents, Long and Short Term Investments

Commitments and Contingencies - Additional Information (Detail)			1 Months Ended		3 Months Ended		12 Months Ended
	Apr. 01, 2022 USD ($)	Nov. 08, 2021 USD ($)	Nov. 30, 2017 USD ($)	May 31, 2017 USD ($)	Mar. 31, 2022 USD ($) Vehicle	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Nov. 30, 2021 USD ($)	Jul. 01, 2013 USD ($)
Commitments And Contingencies [Line Items]
Accrued expenses and other current liabilities					$ 1,100,000		$ 1,100,000
Milestone rights liability					4,800,000		4,800,000
Operating lease costs					288,000	$ 350,000
Financing liability					102,900,000		100,500,000
Financing liability, long term					93,463,000		93,525,000	$ 93,500,000
Financing liability, short term					$ 9,410,000		6,977,000	$ 9,400,000
Payment of long term purchase commitment, amendment fees							$ 2,000,000.0
Supply Agreement expiration period					Dec. 31, 2027
Supply Agreement renewal period					2 years
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List					Other assets
Office Lease
Commitments And Contingencies [Line Items]
Operating lease rent expenses			$ 35,969	$ 40,951
Percentage of annual increase in lease payment			3.00%	3.00%
Reimbursement amount received for tenant improvements			$ 56,325
Office Lease \| Subsequent Event
Commitments And Contingencies [Line Items]
Lease renewal option	66 months
Operating lease rent expenses	$ 79,543
Percentage of annual increase in lease payment	3.00%
Master Lease Agreement with Enterprise \| Vehicle Leases
Commitments And Contingencies [Line Items]
Number of vehicle leases retired \| Vehicle					85
Number of vehicle leases replaced \| Vehicle					85
Number of vehicle leases \| Vehicle					89
Operating lease rent expenses					$ 100,000
Gain or loss recorded for leases removed					500,000
Operating lease, right-of-use asset					1,400,000
Operating lease, liability					1,400,000
1 Casper, LLC
Commitments And Contingencies [Line Items]
Sale price		$ 102,300,000
Lease initial term		20 years
Lease renewal option		4 years
Lease renewal options		renewal options of five years
Lessee,option to extend [true false]		true
Operating lease costs		$ 9,500,000
Lease, description		The total annual rent under the Lease starts at approximately $9.5 million per year, subject to a 50% rent abatement during the first year of the Lease, and will increase annually by (i) 2.5% in the second through fifth year of the Lease and (ii) 3% in the sixth and each subsequent year of the Lease, including any renewal term.
Security deposit		$ 2,000,000.0
Lease repurchase description		the Company has four options to repurchase the Property, in 2026, 2031, 2036 and 2041, for the greater of (i) $102.3 million and (ii) the fair market value of the Property.
Minimum \| 1 Casper, LLC
Commitments And Contingencies [Line Items]
Lease repurchase, amount		$ 102,300,000
Milestone Rights Liability
Commitments And Contingencies [Line Items]
Contingent liability remain payable					65,000,000.0				$ 65,000,000.0
Accrued expenses and other current liabilities					1,100,000
Milestone rights liability					$ 4,800,000
Milestone Rights Liability \| Maximum
Commitments And Contingencies [Line Items]
Contingent liability for milestone payments									$ 90,000,000.0

Property and Equipment, Net (Parenthetical) (Detail) - UT Equipment $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)
Property Plant And Equipment [Line Items]
Construction in progress	$ 7.7
Proceeds from related party	$ 7.1

Investments (Tables)

3 Months Ended

Mar. 31, 2022

Schedule Of Investments [Abstract]

The fair value of the cash equivalents, long- and short-term investments are disclosed below (amounts in millions).

	March 31, 2022
	Investment Level	Amortized Cost (Carrying Value)			Gross Unrealized Holding Losses		Estimated Fair Value
Commercial bonds and paper	Level 2	$	119.5		$	0.8	$	118.8
Money market funds	Level 1		50.7			—		50.7
U.S. Treasuries	Level 2		49.3			0.5		48.8
Total cash equivalents and investments		$	219.5		$	1.3	$	218.3
Less cash equivalents			(53.8	)		—		(53.8	)
Total Investments		$	165.7		$	1.3	$	164.5

	December 31, 2021
	Investment Level	Amortized Cost (Carrying Value)			Gross Unrealized Holding Losses		Estimated Fair Value
Commercial bonds and paper	Level 2	$	115.2		$	0.2	$	115.0
Money market funds	Level 1		21.3			—		21.3
U.S. Treasuries	Level 2		23.9			0.1		23.8
Total cash equivalents and investments		$	160.4		$	0.3	$	160.1
Less cash equivalents			(23.8	)		—		(23.8	)
Total Investments		$	136.6		$	0.3	$	136.3

Borrowings - Schedule of Amortization of Debt Premium and Accretion of Debt Discount and Debt Issuance Cost (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Debt Disclosure [Abstract]
Amortization of debt discount	$ 106	$ 60
Amortization of debt issuance cost	$ 363	$ 124

Earnings Per Common Share ("EPS") - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Parenthetical) (Detail) - RSU	3 Months Ended
	Mar. 31, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Share delivery percentage	300.00%
Valuation assessment percentage	0.00%

Stock-Based Compensation Expense

3 Months Ended

Mar. 31, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation Expense

12. Stock-Based Compensation Expense

During the three months ended March 31, 2022, the Company granted the following awards:

	Three Months Ended
	March 31, 2022
Employee awards:
RSUs		88,415	⁽¹⁾

____________________

(1)	RSUs had a weighted average grant date fair value of $2.72 per share, of which 12,800 RSUs had a cliff vesting period of three years and 75,615 RSUs had a vesting period of four years.

As of March 31, 2022, there was $1.5 million of unrecognized stock-based compensation expense related to options and PNQs, which is expected to be recognized over a weighted average period of approximately 1.20 years, and $9.4 million and $8.6 million of unrecognized stock-based compensation expense related to RSUs and Market RSUs, respectively, which is expected to be recognized over a weighted average period of approximately 2.86 and 1.84 years, respectively.

Total stock-based compensation expense recognized in the condensed consolidated statements of operations as cost of goods sold, cost of revenue – collaborations and services, research and development and selling, general and administrative expense for the three months ended March 31, 2022 and 2021 was as follows (in thousands):

	Three Months Ended March 31,
	2022		2021
RSUs and options	$	2,644	$	1,826
Employee stock purchase plan		162		109
Total stock compensation expense	$	2,806	$	1,935

Employee Stock Purchase Plan

The Company provides all employees, including executive officers, the ability to purchase common stock at a discount under the Company’s 2004 employee stock purchase plan (the “ESPP”). The ESPP is designed to comply with Section 423 of the Internal Revenue Code and provides all employees with the opportunity to purchase up to $25,000 worth of common stock (based on the undiscounted fair market value at the commencement of the offering period) each year at a purchase price that is the lower of 85% of the fair market value of the common stock on either the date of purchase or the commencement of the offering period. An employee may not purchase more than 5,000 shares of common stock on any purchase date. The executives’ rights under the ESPP are identical to those of all other employees.

Collaboration, Licensing and Other Arrangements (Tables)

3 Months Ended

Mar. 31, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Revenue from Collaboration and Services

Revenue from collaborations and services for the three months ended March 31, 2022 and 2021 are as follows (in thousands):

	Three Months Ended March 31,
	2022		2021
UT License Agreement⁽¹⁾	$	1,348	$	8,999
UT CSA Agreement⁽²⁾		694		—
Cipla License and Distribution Agreement		37		36
Other		87		—
Vertice Pharma Co-Promotion Agreement		—		292
Receptor CLA		—		10
Total revenue from collaborations and services	$	2,166	$	9,337

_________________________

(1)	Amounts consist of revenue recognized for Next-Gen R&D Services for the three months ended March 31, 2022 and R&D Services and License for the three months ended March 31, 2021.

(2)	Amount consists of revenue recognized for Manufacturing Services for the three months ended March 31, 2022.

Schedule of Effect of Modification on Transaction Price

Anticipated

Description

Cash Flow

Revenue Allocation⁽¹⁾

Recognition Method

Progress Measure

Revenue

Recognition

(in millions)

Total anticipated cash flow⁽²⁾

463.5

Distinct Performance Obligation

R&D Services and License⁽³⁾

—

Over time

Ratably

Aug 2021 - Oct 2021

⁽⁴⁾

Next-Gen R&D Services⁽⁵⁾

4.8

Over time

Input

% of completion of costs

⁽⁶⁾

Manufacturing Services⁽⁷⁾

458.7

Point in time

Transfer of control

⁽⁸⁾

_________________________

(1)	Allocation is based on management’s assessment of the stand-alone selling price of each performance obligation.

(2)	The total anticipated cash flow includes a transaction price of $64.3 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $399.2 million for future supply of Tyvaso DPI over the remaining term of the CSA.

(3)

(4)	Represents the period when the revenue for the R&D Services performance obligation was recognized.

(5)

(6)

(7)

(8)

Accounts Receivable - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($) Distributor
Accounts Receivable [Line Items]
Number of wholesale distributors \| Distributor	3
Percentage of gross sales from major wholesale distributors	69.00%
Allowance for credit losses for accounts receivable	$ 0.8
Percentage of revenue from major customers collaborations and services	94.00%
United Therapeutics Corporation
Accounts Receivable [Line Items]
Percentage of collaborations and services net accounts receivables	100.00%
Vertice Pharma LLC
Accounts Receivable [Line Items]
Allowance for credit losses for accounts receivable	$ 0.8
Commercial product sales
Accounts Receivable [Line Items]
Percentage of accounts receivable from major wholesale distributors	74.00%

Borrowings - Schedule of Line of Credit Facility Debt and Key Terms (Parenthetical) (Detail) - USD ($)
$ in Millions

1 Months Ended

3 Months Ended

Apr. 30, 2021

Mar. 31, 2021

Mar. 31, 2022

$ 230.0

Prepayment of principal balance

$ 10.0

MidCap Credit Facility | Prior To Midcap Credit Facility Amendment

^[1]

2025-08

LIBOR | MidCap Credit Facility

2024-08

^[1]

6.25%

LIBOR | MidCap Credit Facility | Prior To Midcap Credit Facility Amendment

^[1]

1.00%

2.00%

Mann Group | Non Convertible Promissory Note | Prior to First Amendment

6.75%

7.00%

2024-11

[1]	In April 2021, the Company prepaid $10.0 million principal balance and amended the MidCap credit facility. The interest rate prior to the amendment was one-month LIBOR (2% floor) plus 6.75% and the maturity date was in August 2024.

Fair Value of Financial Instruments - Additional Information (Detail) $ in Thousands	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Nov. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)
Fair Value Of Financial Instruments [Line Items]
Cash and cash equivalents	$ 67,243	$ 124,184		$ 247,833
Financing liability, long term	93,463	93,525	$ 93,500
Financing liability, short term	9,410	6,977	$ 9,400
Note payable, percentage of hypothetical yield				9.0
Money Market Funds
Fair Value Of Financial Instruments [Line Items]
Cash and cash equivalents	$ 67,200	$ 124,200

Commitments and Contingencies - Remaining Purchase Requirements (Detail) - EUR (€) € in Millions	Mar. 31, 2022	Mar. 31, 2021
Purchase Obligation Fiscal Year Maturity [Abstract]
2021		€ 7.0
2022	€ 4.1	8.5
2023	8.8	10.9
2024	14.6	14.6
2025	15.5	15.5
2026	19.4	€ 19.4
2027	€ 9.2

Commitments and Contingencies - Summary of Lease Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Operating lease costs	$ 288	$ 350
Variable lease costs	86	111
Cash paid	$ 442	$ 461

Borrowings - Mann Group Promissory Notes - Additional Information (Detail)
$ / shares in Units, $ in Millions

1 Months Ended

3 Months Ended

12 Months Ended

Apr. 30, 2021

USD ($)

Mar. 31, 2021

USD ($)

Aug. 31, 2019

USD ($)

$ / shares

Mar. 31, 2021

USD ($)

Dec. 31, 2021

USD ($)

Mar. 31, 2022

USD ($)

$ / shares

$ 288.4

Dec. 31, 2025

Nov. 03, 2024

Mann Group | Convertible Promissory Note

$ 230.0

Senior notes, effective interest rate

$ 18.4

^[1]

2.50%

Repayments of debt

$ 35.1

Conversion price of shares | $ / shares

$ 2.50

Conversion of notes to common shares, shares | shares

$ 9.6

4,000,000

Mann Group | Convertible Promissory Note | Accrued Interest

Mann Group | Promissory Notes

$ 0.4

Debt instrument fair value in excess of face amount

18.4

Loss on extinguishment of debt

22.1

Debt premium recognized in additional paid-in capital

$ 22.1

Mann Group | New Loan Arrangement | Convertible Promissory Note

Principal amount per share | $ / shares

No of convertible shares

400

$ 1,000

Conversion price of shares | $ / shares

$ 2.50

Mann Group | New Loan Arrangement | Promissory Notes

Senior notes, effective interest rate

2.50%

7.00%

Debt instrument payment term description

quarterly

Debt instrument, date of first required interest payment

Oct. 01, 2019

Mann Group | Privately Negotiated Exchange Agreement | Loan Arrangement

Common stock price per share | $ / shares

$ 2.50

Mann Group | Privately Negotiated Exchange Agreement | Loan Arrangement | Convertible Promissory Note

Mann Group | Privately Negotiated Exchange Agreement | Loan Arrangement | Non-Convertible Note

$ 35.0

$ 35.1

[1]	In April 2021, the Mann Group convertible note was amended. The interest rate prior to the amendment was 7.00% and the maturity date was in November 2024.

Investments

3 Months Ended

Mar. 31, 2022

Schedule Of Investments [Abstract]

Investments

2. Investments

Held-to-Maturity Investments — Investments consist of highly liquid investments that are intended to facilitate liquidity and capital preservation. As of March 31, 2022, the Company held $95.2 million of short-term investments and $70.5 million of long-term investments. As of December 31, 2021, the Company held $79.9 million of short-term investments and $56.6 million of long-term investments. For the three months ended March 31, 2022, the Company recognized $0.4 million of interest income on investments and $0.3 million of amortization on certain investments. The interest income net of amortization on investments is reflected as interest income, net on the condensed consolidated statement of operations. For the three months ended March 31, 2021, the Company recognized a de minimis amount of interest income on investments. No allowance for credit losses on held-to-maturity securities was required as of March 31, 2022.

Available-for-Sale Investment — The Thirona convertible notes are classified as available-for-sale securities and are included in other assets in the condensed consolidated balance sheet. Available-for-sale investments are subsequently measured at fair value. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income until realized. The Company determines fair value of its available-for-sale investments using level 3 inputs. The Company evaluated the fair value of its investment in Thirona as of March 31, 2022 by applying a Monte Carlo simulation and determined that the fair value was $6.9 million. The fair value of the investment in Thirona as of December 31, 2021 was $3.0 million, which approximated carrying value. For the three months ended March 31, 2022, an unrealized holding loss of $1.1 million was recognized as other comprehensive loss in our condensed consolidated statements of comprehensive loss and condensed consolidated statements of stockholders’ deficit.

The fair value of the cash equivalents, long- and short-term investments are disclosed below (amounts in millions).

	March 31, 2022
	Investment Level	Amortized Cost (Carrying Value)			Gross Unrealized Holding Losses		Estimated Fair Value
Commercial bonds and paper	Level 2	$	119.5		$	0.8	$	118.8
Money market funds	Level 1		50.7			—		50.7
U.S. Treasuries	Level 2		49.3			0.5		48.8
Total cash equivalents and investments		$	219.5		$	1.3	$	218.3
Less cash equivalents			(53.8	)		—		(53.8	)
Total Investments		$	165.7		$	1.3	$	164.5

	December 31, 2021
	Investment Level	Amortized Cost (Carrying Value)			Gross Unrealized Holding Losses		Estimated Fair Value
Commercial bonds and paper	Level 2	$	115.2		$	0.2	$	115.0
Money market funds	Level 1		21.3			—		21.3
U.S. Treasuries	Level 2		23.9			0.1		23.8
Total cash equivalents and investments		$	160.4		$	0.3	$	160.1
Less cash equivalents			(23.8	)		—		(23.8	)
Total Investments		$	136.6		$	0.3	$	136.3

As of March 31, 2022 and December 31, 2021, there was $0.5 million and $0.3 million, respectively, of interest receivable included in our condensed consolidated balance sheets as prepaid expenses and other current assets.

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues:
Total revenues	$ 11,992	$ 17,436
Expenses:
Cost of goods sold	2,284	4,315
Research and development	3,536	2,442
Selling, general and administrative	20,697	17,413
Gain on foreign currency translation	(1,983)	(3,838)
Total expenses	33,248	23,627
Loss from operations	(21,256)	(6,191)
Other (expense) income:
Interest income, net	377	3
Interest expense on financing liability	(2,371)
Interest expense on notes	(2,748)	(6,452)
Other expense		(276)
Total other expense	(4,742)	(6,725)
Loss before provision for income taxes	(25,998)	(12,916)
Net loss	$ (25,998)	$ (12,916)
Net loss per share - basic and diluted	$ (0.10)	$ (0.05)
Shares used to compute net loss per share - basic and diluted	251,887	246,631
Commercial product sales
Revenues:
Total revenues	$ 9,826	$ 8,099
Collaborations and services
Revenues:
Total revenues	2,166	9,337
Expenses:
Cost of revenue	$ 8,714	$ 3,295

Income Taxes

3 Months Ended

Mar. 31, 2022

Income Tax Disclosure [Abstract]

Income Taxes

14. Income Taxes

Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and concluded, in accordance with the applicable accounting standards, that net deferred tax assets should be fully reserved.

The Company has assessed its position with regards to uncertainty in tax positions and has not recognized a liability for unrecognized tax benefits. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax expense. During the three months ended March 31, 2022 the Company did not recognize any interest or penalties. The Company’s tax years since 2017 remain subject to examination by tax authorities.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation Expense (Tables)

3 Months Ended

Mar. 31, 2022

Schedule of Employee Awards and Non-employee Director Award Plan Activity

During the three months ended March 31, 2022, the Company granted the following awards:

	Three Months Ended
	March 31, 2022
Employee awards:
RSUs		88,415	⁽¹⁾

____________________

(1)	RSUs had a weighted average grant date fair value of $2.72 per share, of which 12,800 RSUs had a cliff vesting period of three years and 75,615 RSUs had a vesting period of four years.

Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations

	Three Months Ended March 31,
	2022		2021
RSUs and options	$	2,644	$	1,826
Employee stock purchase plan		162		109
Total stock compensation expense	$	2,806	$	1,935

Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 67,243	$ 124,184	$ 247,833
Restricted cash			158
Total cash, cash equivalents, and restricted cash	$ 67,243	$ 124,184	$ 247,991	$ 67,163

Commitments and Contingencies - Schedule of Lease Term and Discount Rate (Detail)	Mar. 31, 2022	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Weighted average remaining lease term (in years)	2 years 4 months 24 days	2 years 7 months 6 days
Weighted average discount rate	7.30%	7.30%

Inventories - Components of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 3,201	$ 2,703
Work-in-process	3,276	2,522
Finished goods	1,567	1,927
Total inventory	$ 8,044	$ 7,152

Stock-Based Compensation Expense - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common stock under Employee Stock Purchase Plan	$ 740,000	$ 390,000
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common stock under Employee Stock Purchase Plan	$ 2,000	$ 3,000
Issuance of common stock under Employee Stock Purchase Plan (in shares)	233,401	292,981
Employee Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock available for issuance	900,000
Employees Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common stock under Employee Stock Purchase Plan	$ 25,000
Issuance of common stock under Employee Stock Purchase Plan (in shares)	5,000
Employees Awards \| Employee Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Discount on purchase price percentage of fair market value	85.00%
Options and PNQs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense related to options	$ 1,500,000
Unrecognized compensation expense, weighted average period for recognition	1 year 2 months 12 days
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense, weighted average period for recognition	2 years 10 months 9 days
Unrecognized compensation expense related to non-option	$ 9,400,000
Market RSU's
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense, weighted average period for recognition	1 year 10 months 2 days
Unrecognized compensation expense related to non-option	$ 8,600,000

Borrowings - Schedule of Maturities of Our Borrowings (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
2023	$ 6,667
2024	20,000
2025	31,758
Thereafter	230,000
Total principal payments	288,425
Unamortized discount	(1,061)
Debt issuance costs	(5,693)
Total debt — net carrying amount	$ 281,671	$ 281,202

Description of Business and Significant Accounting Policies

Common and Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 31, 2021	Feb. 28, 2018	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Class of Stock [Line Items]
Common stock, shares authorized			400,000,000		400,000,000
Common stock, par value			$ 0.01		$ 0.01
Undesignated preferred stock, shares authorized			10,000,000		10,000,000
Undesignated preferred stock, par value			$ 0.01		$ 0.01
Common stock, shares issued			252,413,434		251,477,562
Common stock, shares outstanding			252,413,434		251,477,562
Preferred stock, shares outstanding			0		0
Debt issuance amount	$ 230,000
Proceeds from market price stock purchase plan			$ 684	$ 0
Market price stock purchase plan			252,176
Employee Stock
Class of Stock [Line Items]
Common stock available for issuance			900,000
Convertible Promissory Note \| Mann Group
Class of Stock [Line Items]
Conversion of notes accrued interest to common shares, value				400
Debt issuance amount				$ 9,600	$ 9,600
Conversion of notes to common shares, shares				4,000,000	4,000,000
2024 Convertible Notes
Class of Stock [Line Items]
Debt issuance amount				$ 5,000
Conversion of notes to common shares, shares				1,666,667
Common Stock
Class of Stock [Line Items]
Issuance of common stock under Employee Stock Purchase Plan (in shares)			233,401	292,981
Controlled Equity Offering Sales Agreement \| Cantor Fitzgerald
Class of Stock [Line Items]
Stock sales agreements date		Feb. 28, 2018
Controlled Equity Offering Sales Agreement \| Cantor Fitzgerald \| Common Stock \| Maximum
Class of Stock [Line Items]
Amount of net proceeds from issuance of securities		$ 50,000
At Market Issuance Sales Agreement
Class of Stock [Line Items]
Sales under sales agreement			$ 0
At Market Issuance Sales Agreement \| Cantor Fitzgerald \| Common Stock
Class of Stock [Line Items]
Amount of net proceeds from issuance of securities				$ 1,900
Number of shares sold during the period				578,063
At Market Issuance Sales Agreement \| Cantor Fitzgerald \| Common Stock \| Weighted Average
Class of Stock [Line Items]
Exchange price per share	$ 3.26			$ 3.26

Income Taxes - Additional Information (Detail)	3 Months Ended
Income Taxes - Additional Information (Detail)	Mar. 31, 2022 USD ($)
Income Tax Disclosure [Abstract]
Unrecognized income tax interest and penalties	$ 0

Investments - Additional Information (Detail) - USD ($)	3 Months Ended
Investments - Additional Information (Detail) - USD ($)	Mar. 31, 2022	Jan. 31, 2022	Dec. 31, 2021	Jun. 30, 2021
Schedule Of Investments [Line Items]
Short-term investments	$ 95,203,000		$ 79,932,000
Long-term investments	70,542,000		56,619,000
Interest on investments	400,000
Amortization on investments	300,000
Allowance for credit losses	0
Unrealized holding loss	1,100,000
Prepaid Expenses and Other Current Assets
Schedule Of Investments [Line Items]
Investment securities	500,000		300,000
Convertible Promissory Note \| Thirona Bio, Inc.
Schedule Of Investments [Line Items]
Investment securities	$ 6,900,000	$ 5,000.0	$ 3,000,000.0	$ 3,000.0

Description of Business and Significant Accounting Policies

3 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

1. Description of Business and Significant Accounting Policies

The unaudited condensed consolidated financial statements of MannKind Corporation and its subsidiaries (“MannKind,” the “Company,” “we” or “us”), have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on February 24, 2022 (the “Annual Report”).

In the opinion of management, all adjustments, consisting only of normal, recurring adjustments, considered necessary for a fair presentation of the results of these interim periods have been included. The results of operations for the three months ended March 31, 2022 may not be indicative of the results that may be expected for the full year.

Basis of Presentation — The condensed consolidated financial statements have been prepared in accordance with GAAP.

The Company believes its resources will be sufficient to fund its operations for the next twelve months from the date of issuance of these condensed consolidated financial statements.

	March 31, 2022		December 31, 2021		March 31, 2021
Cash and cash equivalents	$	67,243	$	124,184	$	247,833
Restricted cash		—		—		158
Total cash, cash equivalents, and restricted cash	$	67,243	$	124,184	$	247,991

Level 1 — Quoted prices for identical instruments in active markets.

Level 3 — Significant inputs to the valuation model are unobservable.

Collaboration, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

20 Months Ended

Oct. 31, 2021

May 31, 2018

Mar. 31, 2022

Mar. 31, 2021

Dec. 31, 2021

Nov. 30, 2020

Oct. 31, 2018

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Deferred revenue - current

$ 1,307,000

$ 827,000

Deferred revenue - non-current

26,116,000

19,543,000

Collaborations and services

11,992,000

$ 17,436,000

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

2,166,000

9,337,000

Commercial product sales

Collaboration and License Agreement | United Therapeutics Corporation

9,826,000

8,099,000

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Upfront payment received

$ 45,000,000.0

Milestone Payment Received

$ 12,500,000

Total anticipated cash flow

^[1]

$ 463,500,000

Deferred revenue

25,700,000

Deferred revenue - current

1,100,000

Deferred revenue - non-current

24,600,000

Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Allocated transaction price

144,500,000

Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services | Transaction Price For The Contractual Obligations

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total anticipated cash flow

64,300,000

Collaboration and License Agreement | United Therapeutics Corporation | Next-Gen R&D Services | Transaction Price For The Performance Obligations

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total anticipated cash flow

$ 399,200,000

Collaboration and License Agreement | United Therapeutics Corporation | Maximum

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Additional option exercise and development milestone payments to be receive

$ 40,000,000.0

Commercial Supply Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Amendment description

Commercial Supply Agreement | United Therapeutics Corporation | Collaborations and services

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Co-Promotion Agreement | Collaborations and services

^[2]

$ 694,000

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Reserve for allowance for credit losses

800,000

Supply and Distribution Agreement | Commercial product sales | Biomm

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

License and Distribution Agreement | Cipla Ltd

$ 0

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Deferred revenue

1,600,000

Deferred revenue - current

100,000

Deferred revenue - non-current

1,500,000

Marketing and distribution agreement date

2018-05

License and Distribution Agreement | Collaborations and services | Cipla Ltd

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

$ 37,000

$ 36,000

[1]	The total anticipated cash flow includes a transaction price of $64.3 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $399.2 million for future supply of Tyvaso DPI over the remaining term of the CSA.
[2]	Amount consists of revenue recognized for Manufacturing Services for the three months ended March 31, 2022

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (25,998)	$ (12,916)
Other comprehensive loss:
Unrealized loss on available-for-sale securities	(1,076)
Comprehensive loss	$ (27,074)	$ (12,916)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.